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CHAPTER I 
INTRODUCTION 
Perioperative Stress and Physiological Responses 
Patients undergoing cardiac surgery or major noncar-
diac surgery are exposed to a variety of preoperative, 
intraoperative and postoperative stresses. During general 
surgical procedures, the patient is stressed by presurgical 
anxiety, induction of anesthesia, intubation, surgical 
trauma and a variety of medications administered during the 
course of the operation. The cardiac surgery patient, while 
being subjected to the usual surgical stresses, is further 
stressed during the cardiopulmonary bypass period when his 
cardiorespiratory functions are taken over by the heart-lung 
bypass machine and abrupt physiological changes such as 
hypotension, hypothermia and hemodilution occur. The 
response of the body to stress induced by surgical trauma, 
antihypertensive drugs or extracorporeal circulation 
involves characteristic changes in plasma catecholamines, 
cortisol and renin activity. 
1 
2 
Catecholamines 
surgical Stress 
The effect of surgical stress on plasma catecholamines 
has been actively debated in recent years. Hammond et al. 
(1956) found no systematic alterations of plasma catechola-
mines in patients undergoing uneventful major surgery. Hine 
et al. (1976) reported no significant elevations in plasma 
catecholamines following induction of anesthesia, skin inci-
sion or thoracotomy in cardiac surgery patients; however, 
elevations in both epinephrine and norepinephrine were seen 
late into the cardiopulmonary bypass period. Butler et al. 
(1977), like the Hine group, found no significant increases 
in plasma catecholamines during the early phases of cardiac 
surgery, but elevations in both epinephrine and norepineph-
rine were seen during the bypass period. This group failed 
to find any significant changes in plasma catecholamines 
following abdominal surgery. 
Many studies have shown that plasma catecholamines are 
elevated in response to intraoperative stress. Anton et al. 
(1964) reported elevated catecholamines in patients during 
both thoracotomy and cardiopulmonary bypass procedures. 
There were also several reports of elevated catecholamines 
3 
during the cardiopulmopary bypass period in patients under-
going myocardial revascularization (Balasaraswathi et al., 
1978 and 1980; Tan et al., 1978; Hoar et al., 1980a; Kim et 
al. 1981). 
A variety of plasma catecholamine responses has been 
reported in patients undergoing abdominal surgery and other 
lower body procedures. Elevated plasma epinephrine and 
norepinephrine levels (Halter et al., 1977), elevated epi-
nephrine levels (Madsen et al., 1978) and elevated norepi-
nephrine levels (Pflug and Halter, 1981) have been shown. 
Thus, while some reports conclude that surgical stress 
does not consistently elevate plasma catecholamines, a sub-
stantial body of evidence indicates that elevations in 
plasma catecholamines occur in response to surgical stress. 
Several investigators have attempted to clarify the 
effects of surgical stress on plasma catecholamines. Bala-
saraswathi et al. (1978) found changes in both epinephrine 
and norepinephrine paralleled changes in blood pressure dur-
ing coronary artery bypass surgery. These authors suggested 
that the elevated plasma catecholamine levels were most 
likely due to a sympathetic response to hypotension. Kim et 
al. (1981) also found elevated norepinephrine and epineph-
rine levels during cardiopulmonary bypass; however, they did 
not find as marked an increase in epinephrine as norepineph-
4 
rine. The authors suggested that changes in norepinephrine 
rather than epinephrine are responsible for the hemodynamic 
changes occurring during cardiopulmonary bypass. But, in a 
direct contradiction of Kim's results, Reves et al. (1982) 
found that it was epinephrine rather than norepinephrine 
that showed the greatest elevation in response to cardiopul-
monary bypass, and these authors suggested that epinephrine 
release is the predominant humoral response to cardiopulmon-
ary bypass surgery. 
Both norepinephrine and epinephrine have been impli-
cated in hemodynamic changes occurring during surgery; how-
ever, the precise role of each has not been clearly defined. 
Anesthesia 
Anesthetics do not have a singular effect on plasma 
catecholamine levels. Most anesthetics either depress or do 
not affect plasma catecholamines when measured shortly after 
induction in patients undergoing surgical procedures. Halo-
thane depressed epinephrine and norepinephrine levels in 
several studies (Perry et al., 1974; Roizen et al., 1974; 
Balasaraswathi et al. 1980). Enflurane either depressed 
(Kim et al., 1981) or did not affect plasma epinephrine and 
norepinephrine levels (Balasaraswathi et al., 1978; Tan et 
al., 1978). On the other hand, morphine either elevated 
5 
(Hasbrouck, 1970) or did not affect plasma catecholamine 
levels (Balasaraswathi et al., 1978; Tan et al., 1978). 
Isoflurane has been reported to depress both epinephrine and 
norepinephrine (Perry et al., 1974) or to elevate epineph-
rine and depress norepinephrine levels (Balasaraswathi et 
al., 1982). Zsigmond (1974) reported an increase in plasma 
norepinephrine levels following ketamine. 
Clinical Application 
Elevated plasma catecholamines, as well as elevated 
cortisol and renin activity, have been associated with post-
operative hypertension, which may present a serious problem 
to cardiac surgery patients. Hypertension in the immediate 
postoperative period following myocardial revascularization 
has been reported to occur in 33% (Estafanous et al., 1973) 
to 58% (Hoar et al., 1976) of these patients. Untreated and 
sustained hypertension can have deleterious effects in cer-
tain patients. Some of these dangers include bleeding from 
deep and superficial incisions, leakage at suture lines, and 
an increase in the susceptibility of patients with general-
ized atherosclerosis to cerebrovascular accidents (Viljoen 
et al., 1976). 
Van Ackern et al. (1979) advised that patients with 
coronary artery disease should be protected against hyper-
6 
tensive episodes; the risk of myocardial infarction is 
increased when an oxygen imbalance exists in the coronary 
artery supply-demand relationship. Hypertension, which 
increases the oxygen demand by increasing the work load of 
the heart, adversely affects myocardial oxygenation and is 
potentially harmful to patients with ischemic heart disease. 
In the same vein, Hoar et al. (1980a) have suggested that 
the fall in blood pressure that often follows anesthesia 
induction may be beneficial to patients with ischemic heart 
disease. 
Hypertension can have adverse effects on patients 
undergoing surgical correction of cerebral aneurysms as well 
as on patients with impaired heart function. That is, the 
rupture of an intracranial aneurysm can result in immediate 
or subsequent fatal hemorrhage (Skultety and Nishioka, 
1966). Because nitroprusside is frequently used to induce 
hypotension for correction of intracranial aneurysms, 
rebound hypertension occurring on discontinuation of nitro-
prusside can jeopardize the patient's recovery (Skultety and 
Nishioka, 1966). 
In cardiac surgery, elevated catecholamine levels may 
reflect a reflex response to the hypotension induced during 
the initial cardiopulmonary bypass period. This reflex 
response is thought to be mediated via the baroreceptors, 
7 
since they play a key role in short-term adjustments of 
blood pressure. Baroreceptors, which are stretch receptors 
located in the carotid sinus and aortic arch, are sensitive 
to changes in blood pressure (Berne and Levy, 1977). A 
reduction in blood pressure results in a reduction in the 
baroreceptor firing rate. This activates the medullary 
vasomotor center, increasing sympathetic activity and cate-
cholamine release, which then leads to an increase in blood 
pressure and heart rate. 
Elevated plasma catecholamine levels during cardiac 
surgery might also be associated with the period of hypoth-
ermia to which the patient is exposed during surgery. 
Hypothermia, which slows the heart and depresses the body's 
metabolism, causes the hypothalamic temperature-regulating 
center to be activated. This leads to increased sympathetic 
activity, resulting in vasoconstriction and heat conserva-
tion (Guyton, 1976). Plasma catecholamine levels are 
increased during normothermic (33-37°C) and moderate hypo-
thermic (27-31°C) cardiopulmonary bypass, but less so with 
the latter. With deep hypothermia (<27°C) the epinephrine 
increase does not occur. Plasma norepinephrine levels 
increase similiar to moderate hypothermia (Replogle et al., 
1962, Anton et al., 1964). 
8 
During noncardiac abdominal surgery Halter et al. 
(1977) reported that changes in epinephrine and norepineph-
rine correlated well with changes in mean arterial pressure. 
These authors suggested that during this type of surgery, 
hypertension probably reflects an adrenergic response to 
pain rather than a reflex reponse to hypotension. In any 
event, in both cardiac and noncardiac surgery, elevations in 
plasma catecholamines have been associated with hypertensive 
episodes. 
Elevated catecholamine levels, which may be harmful to 
certain patients, may be functionally necessary for others. 
Increased sympathetic activity increases both heart rate and 
the contractile strength of the heart. Patients who require 
increased sympathetic activity for sufficient cardiac out-
put, i.e. valvular disease, could experience reduced cardiac 
performance if catecholamine levels were lowered. 
In addition to the effects of catecholamines on blood 
pressure, several investigators have attempted to correlate 
plasma catecholamines with other physiological conditions. 
The results of the Vlachakis et al. (1981) study suggests 
that elevated plasma catecholamines may increase platelet 
aggregation and consequently promote postoperative thrombo-
embolism. Other investigators, however, have not been suc-
cessful in correlating plasma catecholamine levels with 
physiological conditions. 
9 
Halter et al. (1977) was unable 
to correlate changes in epinephrine and norepinephrine dur-
ing abdominal surgery to hypoxemia or hypothermia. Further-
more, Turton et al. (1977) found no correlation between ele-
vated plasma catecholamine levels and mean diastolic 
pressure, heart rate or respiration rate. 
In conclusion, changes in plasma catecholamines may 
reflect the response of the body to many surgical and non-
surgical stresses. The exact role that elevated catechola-
mines play in homeostasis following intraoperative and post-
operative stresses has not been clearly defined. However, 
elevations in plasma catecholamines can be either harmful or 
beneficial, depending on the interaction between the cardiac 
status of the patient and type of surgical stress that he is 
scheduled to undergo. 
Cortisol 
Surgical Stress 
Cortisol has consistently been shown to be elevated in 
response to surgical stress. With regard to noncardiac sur-
gery, elevated plasma cortisol has been reported during 
10 
abdominal surgery (Lewis, 1963; Plumpton and Besser, 1969; 
Bromage et al., 1971; Newsome and Rose, 1971; Cosgrove and 
Jenkins, 1974; Kehlet et al., 1974; Madsen et al. , 1976 and 
1977; Engquist et al., 1977), thoracic surgery (Bromage et 
al., 1971), hip surgery (Plumpton and Besser, 1969), tympan-
oplasty (Madsen et al., 1976) and in the undefined category 
of general surgery (Reier et al., 1973; Gillet al., 1975; 
Oyama et al., 1975). Plumpton and Besser (1969) studied the 
long-term response of cortisol to noncardiac surgery by mon-
itoring plasma cortisol levels hourly during major surgery 
and then daily for six days postoperatively. These authors 
found a rapid rise in plasma cortisol levels during surgery, 
a continued rise during the first six hours of the postoper-
ative period, and then a gradual decrease over the next 
24-48 hours. 
Madsen et al. (1976) reported that the magnitude of 
elevated plasma cortisol levels is related to the intensity 
of the surgical stress. These authors measured plasma cor-
tisol levels during two different types of surgery and found 
that plasma cortisol levels during hysterectomy were signif-
icantly higher than cortisol levels during tympanoplasty. 
The cortisol response during cardiac surgery was dem-
onstrated by Taylor et al. (1976). These authors compared 
plasma cortisol levels in patients undergoing cardiac sur-
11 
gery either with or without the use of heart-lung bypass. 
In the nonbypass patients, the cortisol response to cardiac 
surgery was similar to that previously described for noncar-
diac surgery, with the levels peaking late into the opera-
tive procedure and then gradually decreasing over the next 
48 hours. In bypass patients, plasma cortisol levels were 
elevated following surgical stress, decreased during the 
bypass period, peaked 24 hours after the operation, and 
remained elevated 48 hours postoperatively. 
Oka et al. (1981) compared plasma cortisol levels in 
patients undergoing cardiac surgery for valvular or coronary 
artery bypass surgery. In accordance with the results of 
the Taylor et al. (1976) study, coronary artery bypass 
patients showed increased plasma cortisol levels in response 
to surgery and these levels continued to rise postopera-
tively. The response of the valvular surgery patients, how-
ever, differed from that of the coronary artery bypass 
patients in both absolute levels and pattern of response. 
That is, valvular surgery patients showed lower plasma cor-
tisol levels than coronary artery bypass patients. Also the 
peak cortisol response in valvular surgery patients was seen 
at the end of the cardiopulmonary bypass period rather than 
late into the postoperative period. 
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Plasma cortisol levels do increase in patients under-
going both cardiac and noncardiac surgery. Furthermore, the 
pattern of the cortisol response varies with different sur-
gical procedures. Also, steriods have been demonstrated to 
interfer with nonneuronal catecholamine reuptake (Iverson 
and Salt, 1970), suggesting that plasma catecholamine levels 
may be influenced by cortisol. Furthermore, recent evidence 
suggests that in the periphery uptake 2 may have a more 
important role than uptake 1 (Chan and Kalsner, 1982). 
Anesthesia 
The effects of general anesthesia on plasma cortisol 
levels for both cardiac and noncardiac surgery patients have 
been reported by many investigators. These studies have 
shown that cortisol levels remained relatively stable fol-
lowing the administration of a variety of anesthetic agents 
including enflurane, nitrous oxide-oxygen-d-tubocurare, hal-
othane, isoflurane and nitrous oxide-oxygen-fentanyl (Lewis, 
1963; Oyama et al., 1975; Yokota et al., 1977; Oyama et al., 
1979; Oka et al., 1981). The poststress elevations in 
plasma cortisol levels are probably related to the stress 
itself, rather than to the anesthetic agent administered to 
the patient. 
13 
Clinical Application 
Oka et al. (1981) have suggested that plasma cortisol 
levels following surgery sometimes may be a factor in the 
patients' ultimate prognosis. They suggest that the rela-
tively poor postoperative recovery seen in critically ill 
valvular surgery patients as compared to that of patients 
undergoing coronary artery bypass surgery may be related to 
lower plasma cortisol levels in valvular surgery patients. 
Also, it is well known that patients with adrenocortical 
insufficiency often experience cardiovascular instability 
during surgery without prior administration of glucocorti-
coids. 
On the other hand, elevated plasma cortisol levels may 
not always be beneficial to patients undergoing the stress 
of surgery. In patients with hyperadrenocortical function 
elevated cortisol levels may be harmful. Madsen et al. 
(1977) have suggested that patients suffering from labile 
diabetes have a high surgical morbidity and might benefit 
from a reduction in cortisol levels. Furthermore, Turndorf 
(1973) has suggested that very high cortisol levels might be 
"antihomeostatic11 since the highest cortisol levels in the 
Reier et al. study (1973) occurred in II • II nonsurv1vors. 
Thus, plasma cortisol levels have been shown to 
increase in response to both cardiac and noncardiac surgery. 
14 
Although increased cortisol levels may be beneficial to cer-
tain surgical patients, there are instances where such ele-
vations may actually be detrimental to the patients' recov-
ery. 
Renin Activity 
The renin-angiotensin system plays an important role 
in maintaining arterial blood pressure, fluid volume and 
electrolyte balance. Although renin itself is not a vasoac-
tive substance, it acts in the general circulation to gener-
ate angiotensin I, which is in turn converted to angiotensin 
II, a very potent vasoconstrictor. Because an inexpensive 
and reliable assay for angiotensin II has not yet been 
developed, plasma renin activity rather than plasma angio-
tensin II levels are frequently taken to reflect renin-angi-
otensin system activity. 
Surgical Stress 
Both cardiac and noncardiac surgery have been associ-
ated with increased plasma renin activity (Yogo et al., 
1973; Favre et al., 1974; Oyama et al., 1979; Philbin et 
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al., 1979; Lappas et al., 1981). In both cardiac and abdom-
inal surgery, the response of the renin-angiotensin system 
to surgical stress tends to be somewhat delayed. Oyama et 
al. (1979) found that plasma renin activity was not 
increased until 30 minutes after abdominal surgery. A simi-
lar delay was reported by Philbin et al. (1979) in patients 
undergoing cardiac surgery. Also Favre et al. (1974) 
reported a marked increase in plasma renin activity, but not 
until 20 minutes after the onset of cardiopulmonary bypass. 
Not all investigators, however, have reported elevated 
plasma renin activity following surgical stimulation. Hoar 
et al. (1980a) did not find significant elevations in plasma 
renin activity either following surgical stimulation or dur-
ing cardiopulmonary bypass. Their patients, however, had 
been pretreated with propranolol, which has been shown to 
block renin release (Buhler, 1980). Moreover, Yun et al. 
(1979) did not observe a rise in plasma renin activity after 
laparotomy, but the anesthetic used in this study was pento-
barbital, which the authors point out decreases plasma renin 
activity over an extended period of time (Yun et al., 1979). 
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Anesthesia 
Many anesthetic agents do not significantly affect 
plasma renin activity. For example, enflurane, methoxyflu-
rane, ether and morphine neither increase nor decrease 
plasma renin activity (Bailey et al., 1975; Miller et al., 
1977; Oyama et al., 1979). Elevations in plasma renin 
activity, however, were reported in one study following hal-
othane anesthesia (Oyama et al., 1979). Yun et al. (1979) 
reported that pentobarbital had a biphasic effect on plasma 
renin activity, increasing during the first hour after 
injection and decreasing for the next 4-1/2 hours. 
Clinical Application 
The results of several studies suggest that elevated 
plasma renin activity might be involved in perioperative 
hypertension. Taylor et al. (1977) compared plasma angio-
tensin II levels in patients undergoing cardiac surgery with 
and without cardiopulmonary bypass. These authors found a 
marked rise in plasma angiotensin II levels in the bypass 
patients that persisted over two hours postoperatively. 
Because hypertension is often seen in the first few hours 
after cardiac bypass surgery, they proposed that elevated 
angiotensin II levels produce the vasopressor response and 
subsequent hypertension. 
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Roberts et al. (1977) also presented evidence to sug-
gest that increased renin-angiotensin system activity might 
be a factor in systemic hypertension seen during coronary 
artery bypass surgery. In this study, patients who became 
hypertensive during surgery had higher plasma renin activity 
levels than patients who did not develop hypertension. 
Also, these authors found a positive correlation between 
mean arterial pressure and plasma renin activity. The evi-
dence suggests that the renin-angiotensin system may play a 
role in perioperative hypertension which can pose a risk to 
certain surgical patients. 
In addition to the elevated plasma renin activity seen 
following the stress of surgery and cardiopulmonary bypass, 
plasma renin activity often increases following nitroprus-
side-induced hypotension (Kaneko et al., 1967; Miller et 
al., 1977; Abukhres et al., 1979; Khambatta et al. , 1979; 
Cottrell et al., 1980; Delaney and Miller, 1980; Stanek et 
al., 1981). In some patients, following termination of the 
nitroprusside infusion, rebound hypertension occurs. 
Plasma renin activity may be an important factor mediating 
this rebound hypertension. Cottrell et al., (1980) state 
that the half-life of renin activity is approximatley 30 
minutes and the half-life of nitroprusside is only 1-2 min-
utes· The authors suggest that the rebound hypertension 
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following nitroprusside-induced hypotension probably results 
from the slow removal of renin from the circulation as com-
pared with the rapid clearance of nitroprusside. Contrac-
tion of vascular smooth muscle then no longer would be 
countered by nitroprusside-induced vasodilation. 
Further support for the involvement of the renin-angi-
otensin system in this rebound hypertension comes from 
Abukhres et al. (1979). These authors showed that rebound 
hypertension did not occur when the primary source of renin 
was eliminated by nephrectomy. They also showed that the 
rebound hypertension was markedly attenuated when renin 
release was blocked by propranolol or when generation of 
angiotensin II was blocked with a converting-enzyme inhib-
itor. 
Other investigators have supported the position that 
renin release rather than sympathetic stimulation causes the 
rebound hypertension following a nitroprusside infusion. 
Cottrell et al. (1980) concluded that catecholamines are 
probably not involved in this rebound hypertension because 
tachycardia was not associated with the elevated blood pres-
sure. Moreover, Rawlinson et al., (1978) showed that 
although epineprhine and norepinephrine were elevated during 
nitroprusside infusion, both approached preinfusion levels 
15 minutes after the infusion ended. The Rawlinson evidence 
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is not conclusive, however, because these authors did not 
report mean arterial pressure following the termination of 
the nitroprusside infusion. Rebound hypertension may not 
have occurred in their patients. In a later study, Delaney 
and Miller (1980) found that while nitroprusside was being 
infused at a constant rate, blood pressure fell signifi-
cantly and then progressively increased. However, when the 
renin-angiotensin system was blocked with saralasin, an 
angiotensin II antagonist, blood pressure remained at a con-
stant depressed level during the nitroprusside infusion and 
no rebound hypertension was seen. Because no increase in 
blood pressure was seen during renin-angiotensin system 
blockade, these authors concluded that "other means of blood 
pressure support (e.g., catecholamines) are not operative in 
this setting" (p. 155). However, catecholamines were not 
measured in this study. Angiotensin II is known to facili-
tate sympathetic transmission (Swales, 1979); thus, blockade 
of angiotensin II could have also attenuated the catechola-
mine response to nitroprusside. 
In summary, plasma renin activity has been shown to be 
elevated in response to surgical and hypotensive stresses, 
but not in response to most anesthetics. Also, the renin-
angiotensin system probably plays an important role in the 
hypertension that often occurs following surgical stimula-
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tion and nitroprusside infusions. Because hypertensive epi-
sodes can be harmful in certain clinical settings, it may be 
beneficial to pharmacologically blunt such untoward rises in 
plasma renin activity. 
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Attenuation of Stress Responses by Benzodiazepines 
The ability to manipulate plasma catecholamine, corti-
sol and renin activity levels may be of benefit in the clin-
ical management of some patients. In light of the previ-
ously discussed theoretical association between elevated 
blood pressure and elevated plasma catecholamines and renin 
activity, surgical patients with ischemic heart disease 
might benefit from an attenuation of stress-induced eleva-
tions in catecholamines (Van Ackern et al., 1979; Hoar et 
al., 1980a) or renin activity (Taylor et al., 1977; Roberts 
et al., 1977). Also, elevated blood pressure can be espe-
cially harmful to patients with intracranial aneurysms 
(Skultety and Nishioka, 1966), and in the perioperative 
period these patients might benefit from pharmacologically 
blunting elevated plasma catecholamines and renin activity. 
Moreover, surgical patients with hyperadrenocortical func-
tion or labile diabetics might benefit from a reduction in 
stress-induced elevations in plasma cortisol levels (Madsen 
et al., 1977). The results of several studies suggest that 
the benzodiazepines might effectively antagonize these com-
pensatory hormonal responses which often occur during the 
course of surgery. 
Pharmacological Profile of Diazepam, Lorazepam and 
Midazolam 
Diazepam 
Chemistry and Pharmacology 
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Diazepam, which is probably the most widely used ben-
zodiazepine, has a variety of therapeutic actions. Diazepam 
has been used for producing mild sedation and managing anxi-
ety, tension and convulsive states, and more recently it has 
been used as a premedicant and as an adjuvant to intravenous 
anesthesia. 
Pharmacokinetic studies indicate that diazepam has a 
rapid onset of action and a prolonged duration of action. 
Jones et al. (1979) reported induction of anesthesia within 
94-158 seconds of diazepam injections, and Hillestad et al. 
(1974) found that within 15 minutes of diazepam injections, 
maximum clinical effects reflected in sleepiness, coordina-
tion difficulties, mental clouding and amnesia were 
recorded. The prolonged effects of diazepam are probably 
due to an elimination half-life of 21 to 37 hours, a very 
large volume of distribution (0.95 L/kg) and slow clearance 
rate (0. 35 ml/min/kg) as well as extensive (96. 8%) plasma 
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protein binding (Kaplan et al., 1973; Klotz et al., 1976). 
Furthermore, certain tissues of the brain, kidney, liver, 
myocardium and digestive system have been shown to rapidly 
take up diazepam and then slowly release it (Mandelli et 
al., 1978). 
The biotransformation of diazepam leads to the forma-
tion of two important metabolites, desmethyldiazepam and 
oxazepam, both of which are active (Kaplan et al., 1973; 
Mandelli et al., 1978). Desmethyldiazepam, the major metab-
olite measured in the bloodstream, is formed by demethyla-
tion of diazepam and has an elimination half-life of 50-99 
hours, which is even longer than that of diazepam. Oxaze-
pam, formed primarily from hydroxylation of desmethyldia-
zeparn, undergoes glucuronide conjugation and this then 
becomes the major urinary metabolite. 
A distinct disadvantage of diazepam is that it is not 
water soluble. Consequently, injectable diazepam is pre-
pared in an organic solvent such as propylene glycol. 
The strucutral formula of diazepam is: 
Cardiovascular and 
Respiratory Effects 
CH1 0 I , 
OC(->· 
6 
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Numerous studies have indicated that the circulatory 
and respiratory effects of diazepam are mild and often clin-
ically insignificant. In an early study, no significant 
decreases in respiration rate, heart rate, systolic and 
diastolic blood pressures, or changes in arterial blood 
chemistry were found in patients premedicated and induced to 
anesthesia with diazepam (McClish, 1966). The only compli-
cations noted in this study were several complaints of pain 
on injection and a small percentage of cases of venous 
thrombosis and thrombophlebitis at the site of injection. 
Later studies tended to confirm the lack of deleterious 
effects of diazepam on the cardiovascular and respiratory 
systems. When statistically significant decreases in heart 
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or lung function were found, as reflected most often in 
decreases in blood pressure or heart rate, these effects 
were not considered to be clinically significant (Cote et 
al., 1974; Markiewicz et al., 1976; McCammon et al., 1980; 
samuelson et al., 1981). 
The results of several studies have suggested that 
diazepam might actually be beneficial to some cardiac sur-
gery patients. Ikram et al. (1973) measured myocardial 
blood flow by the 13 3 Xe clearance method and showed that 
diazepam increased myocardial blood flow in patients with 
diseased and normal coronary arteries. On the other hand, 
Cote et al. (1974) measured myocardial blood flow by ther-
modilution in a similiar patient population, but they did 
not find that diazepam increased coronary blood flow. The 
inconsistancy in the results of the Ikram and Cote studies 
is probably a function of the different methods used in 
these two studies to measure coronary blood flow. 
A decrease in myocardial oxygen consumption was 
reported by Cote et al. (1974). Daniell (1975) confirmed 
these results, and also found that diazepam treatment was 
associated with an increase in coronary blood flow. 
In summary, diazepam appears to be devoid of clini-
cally significant untoward hemodynamic or respiratory 
effects. Furthermore, the reported increase in myocardial 
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blood flow and decrease in oxygen consumption suggest that 
diazepam would be a good premedicant for certain patients 
with compromised heart or lung function. 
Lorazepam 
Chemistry and Pharmacology 
Lorazepam is a benzodiazepine that resembles diazepam 
in many of its clinical effects. Like diazepam, lorazepam 
has sedative-hypnotic, muscle relaxant, antianxiety and 
anticonvulsant properties, and is currently being used as a 
premedicant for general anesthesia (Alps et al., 1973; Wil-
son, 1973; Conner et al., 1978; Ameer and Greenblatt, 1981). 
The clinical effects of lorazepam are quite similar to those 
of diazepam. Lorazepam is four to five times more potent 
than diazepam (Dundee et al., 1979), only 88-92% bound to 
plasma protein (Greenblatt, 1981), and there are distinct 
pharmacological differences between these two benzodiaze-
pines. 
Lorazepam has a considerably longer onset and duration 
of action than diazepam. Conner et al. (1978) compared the 
onset of the sedative and antianxiety effects of equipotent 
doses of lorazepam and diazepam and found that the diazepam 
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group showed a peak effect in four minutes, but the loraze-
pam peak was not seen for 32 minutes. Conner et al. con-
cluded that while the peak effects of diazepam and lorazepam 
did not differ significantly, the time taken to achieve the 
peak effect was significantly delayed in the lorazepam 
group. These results were confirmed by Dundee et al. (1979) 
who further showed that the duration of action of lorazepam 
is three to four times longer than that of equivalent doses 
of diazepam. Lorazepam' s delayed onset of action and pro-
longed duration of action as compared with diazepam are 
somewhat perplexing since lorazepam's half-life (13.2 hours) 
and volume of distribution (0. 84 L/kg (Greenblatt et al., 
1977)) are considerably less than the values reported for 
diazepam. Furthermore, unlike diazepam, lorazepam does not 
have an active metabolite, since lorazepam is rapidly con-
verted to its major metabolite, lorazepam glucuronide 
(Elliott, 1976). 
Ameer and Greenblatt (1981) have commented on the 
somewhat paradoxical clinical profile of lorazepam and con-
cluded that, "because the lipophilicity of lorazepam is much 
less than that of the prototype benzodiazepine, diazepam, 
the onset of clinical activity of intravenous lorazepam fol-
lowing a single dose is much slower than that of diazepam. 
This effect can be attributed to the slower rate of loraze-
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pam's passage across the blood brain barrier" (p.162). 
These authors further suggest that "since the extent of tis-
sue distribution of lorazepam also is less than that of 
diazepam, single doses of lorazepam would appear to have a 
longer duration of action than will single doses of diaze-
pam" (p.162). 
Unfortunately, lorazepam, like diazepam, is not water 
soluble and is prepared for injection in a propylene glycol 
solution. However, although there are reports of thrombosis 
and phlebitis after intravenous injection of lorazepam, 
these complications are seen less frequently than following 
diazepam injections (Hegarty and Dundee, 1977; Dundee et 
al., 1979). The chemical structure of lorazepam, which is 
similar to that of diazepam is: 
Cl 
~ 0 N~OH 
-N 
Cl 
Cardiovascular and 
Respiratory Effects 
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Only minimal cardiovascular and respiratory effects 
have been seen following the administration of lorazepam. 
Alps et al. (1973) found that doses of lorazepam that were 
three times those used therapeutically produced only slight 
changes in heart rate, blood pressure and myocardial con-
tractile force. However, at doses significantly above ther-
apeutic doses, some depression in heart rate and blood pres-
sure were reported. Knapp and Fierro (1974) also evaluated 
the cardiopulmonary safety of lorazepam and found no signif-
icant electrocardiographic, hemodynamic or respiratory 
changes in noncardiac surgery patients receiving lorazepam. 
Furthermore, Gale and Galleon (1976) used lorazepam as a 
premedicant in gynecological patients and reported that 
pulse rate, blood pressure and respiration were remarkably 
stable in all patients. 
In summary, lorazepam is a benzodiazepine that has a 
prolonged onset and duration of action and clinical effects 
that are similar to those of diazepam. Because lorazepam 
causes minimal cardiovascular and respiratory depression, it 
would appear to be an ideal premedicant in patients with 
compromised cardiopulmonary function. It would also appear 
to be a good candidate for further investigation to deter-
mine if it might blunt elevations in catecholamines, corti-
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sol and renin activity often seen in response to intraopera-
tive stresses. 
Midazolam 
Chemistry and Pharmacology 
Midazolam is an investigational benzodiazepine that 
resembles both diazepam and lorazepam in its clinical 
effects. Like these benzodiazepines, midazolam has anxyo-
lytic, anticonvulsant, sleep-inducing, muscle-relaxant and 
sedative effects, and is currently being tested for induc-
tion of anesthsia (Gamble et al., 1981; Pieri et al., 1981; 
Schwander and Sansano, 1981). Although midazolam resembles 
diazepam and lorazepam in its therapeutic actions, midazolam 
does have some interesting characteristics that differenti-
ate it from the other benzodiazepines. 
Like diazepam, midazolam has a rapid onset of action 
with sleep occurring from 1-1/2 to 3 minutes following its 
intravenous administration (Reves et al., 1978; Jones et 
al. , 1979; Gamble et al., 1981). Midazolam is reported to 
be twice as potent as diazepam (Dundee, 1980). Unlike both 
diazepam and lorazepam, the clinical effects of midazolam 
are of short duration, with drowsiness lasting for approxi-
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mately two hours and mental clouding for approximately one 
hour (Forster et al., 1980). 
The time course of the clinical effects of midazolam 
correlates well with its pharmacokinetic profile. Following 
an intravenous injection of midazolam, the drug is rapidly 
and widely distributed with a volume of distribution of 1.14 
L/kg (Smith et al., 1981). In contrast to most benzodiaze-
pines, midazolam shows a relatively short elimination half-
life of 1.77-2.5 hours and is rapidly cleared from plasma at 
6. 38 ml/min/kg. It is similar to other benzodiazepines in 
that it is extensively (94%) bound to plasma proteins (Smith 
et al., 1981; Allonen et al., 1982). The short duration of 
midazolam's clinical effects may be related not only to the 
short elimination half-life and large volume of distribu-
tion, but also to the biological inactivity of midazolam's 
metabolites . These metabolites are rapidly formed from 
midazolam by hydroxylation and subsequent conjugation with 
glucuronic acid (Heizmann and Ziegler, 1981; Vree et al., 
1981). 
The pharmacokinetic profile of midazolam, when con-
trasted with that of diazepam and lorazepam, shows midazolam 
to be a unique benzodiazepine. Midazolam resembles diazepam 
in having a fast onset of action, but differs from both 
diazepam and lorazepam in having a short duration of action. 
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The elimination half-life of midazolam is considerably 
shorter than that of either diazepam or lorazepam, the 
extent of plasma protein binding is intermediate between 
that reported for diazepam and lorazepam, and the volume of 
distribution and rate of clearance are.higher than the val-
ues reported for either diazepam or lorazepam. However, 
despite all the pharmacokinetic differences in these three 
benzodiazepines, their clinical effects are quite similar. 
In addition to the pharmacological differences between 
midazolam and the other benzodiazepines used in this study, 
midazolam has some unique chemical properties. From the 
following chemical structure of midazolam, it can be seen 
that midazolam, unlike diazepam and lorazepam, is an imida-
zole benzodiazepine: 
Cl 
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Midazolam exhibits a pH-dependent opening of the benzodiaze-
pine ring. At a pH less than 4.0 the ring opens reversibly 
producing a water-soluble compound. However, at a more 
physiological pH, the ring closes and the compound becomes 
lipid rather than water soluble (Dundee, 1979). Midazolam 
does not require a propylene glycol vehicle. Consequently, 
injections of midazolam rarely result in pain on injection 
or venous irritation (Fragen et al., 1978; Dundee et al., 
1980; Gamble et al., 1981). 
Cardiovascular and 
Respiratory Effects 
For the most part, midazolam has been shown to have 
only modest cardiopulmonary actions. The most frequently 
reported hemodynamic actions of midazolam in human volun-
teers and experimental animals are a slight decrease in mean 
arterial pressure and an increase in heart rate (Reves et 
al., 1978; Jones et al., 1979; Forster et al., 1980). 
Although many investigators have found respiration remains 
relatively stable following midazolam injections, brief epi-
sodes of apnea have been reported (Reves et al., 1978; For-
ster et al., 1980). 
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Midazolam has been administered to patients undergoing 
cardiac surgery (Reves et al., 1979; Samuelson et al., 1981; 
Morel et al., 1981). In all of these studies, midazolam was 
used for induction of anesthesia. The authors reported 
slight, but clinically acceptable, cardiovascular and 
respiratory depression, and concluded that midazolam was 
safe and acceptable for use in patients with cardiac dys-
function. 
Midazolam is an imidazole benzodiazepine with a fast 
onset of action, relatively short duration of action, lack 
of pain on injection and minimal cardiovascular and respira-
tory effects. Midazolam, when finally released for general 
use by the Food and Drug Administration, would appear to 
have widespread use in anesthesia and surgical patients. A 
study of its effects on plasma catechoalmines, cortisol and 
renin activity during hypotensive and surgical stresses is 
indicated. 
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Effects of Benzodiazepines on Plasma Catecholamines 
Over the past decade Zsigmond and his associates have 
reported that diazepam is effective in preventing the car-
diovascular stimulation caused by ketamine anesthesia (Zsig-
mond et al., 1974; Kothary et al., 1975; Kumar et al., 1978; 
Kumar et al., 1980; Zsigmond et al., 1980). In this series 
of studies, involving both cardiac and noncardiac surgery 
patients, ketamine administered in the absence of diazepam 
resulted in tachycardia, hypertension and increased sympa-
thetic activity. However, when diazepam was administered 
prior to ketamine, the circulatory side effects of ketamine 
were absent and no significant elevations were seen in 
either epinephrine or norepinephrine levels. 
Further beneficial effects of diazepam were shown by 
Melsom et al. (1976). In this study, patients admitted to 
the coronary care unit with acute myocardial infarction were 
divided into a diazepam group and a control group. Patients 
treated with diazepam showed a marked decrease in urinary 
catecholamines compared with patients not given diazepam. 
These authors also reported that the incidence of severe 
cardiac arrhythmias was less frequent in the diazepam group. 
Additionally, Hoar et al. (1981) showed that diazepam 
may reverse anestbesia-induced elevations in plasma cate-
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cholamines. The authors showed that significant elevations 
in plasma epinephrine and norepinephrine normally seen fol-
lowing morphine anesthesia were reversed following the 
administration of diazepam. 
The effects of diazepam on catecholamines during sur-
gical stress are difficult to ascertain from the studies 
reported in the literature. In the Hoar et al. (1981) 
study, diazepam reversed morphine-induced elevations in cat-
echolamines; however, following surgical stimulation the 
catecholamines rose to levels well above baseline levels. 
Since a diazepam-free control group was not included in this 
study, it cannot be determined whether the postsurgical lev-
els would have been even greater in the absence of diazepam. 
However, this is probably the case since the postsurgical 
catecholamine levels were well below the postmorphine lev-
els, and anesthesia is generally considered to be a milder 
stress than surgery. 
Other studies have reported significant elevations in 
plasma catecholamines following diazepam. Significant ele-
vations in plasma catecholamines during the cardiopulmonary 
bypass period were seen in patients premedicated with diaze-
pam followed by enflurane-nitrous oxide anestheisa (Tan et 
al., 1978), morphine-nitrous oxide anesthesia (Balasaraswa-
thi et al., 1978) or fentanyl-oxygen anesthesia (Lappas et 
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al., 1981). Furthermore, Reves et al. (1982) found that 
diazepam given prior to the onset of cardiopulmonary bypass 
failed to attenuate subsequent significant elevations in 
catecholamines. However, all of these studies, like the 
Hoar study, lacked a diazepam-free control group. Also, a 
variety of premedications were given to the patients in 
these studies that could have influenced the catecholamines 
independent of surgical and bypass stresses. Diazepam can 
attenuate anesthesia-induced elevations in catecholamines; 
however, the effects of diazepam on surgery-induced eleva-
tions in catecholamines are not well defined. 
Effects of Benzodiazepines on Plasma Cortisol Levels 
Fewer studies have been conducted on the effects of 
benzodiazepines on plasma cortisol and renin activity than 
their effects on plasma catecholamines. However, there are 
some indications that benzodiazepines can counteract 
stress-induced elevations in cortisol. James and Fisher 
(1970) premedicated gynecological patients with nitrazepam, 
a benzodiazepine structurally similar to diazepam, and found 
plasma cortisol levels significantly reduced in response to 
surgical stress. A similar reduction in plasma cortisol 
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levels was later found by Wesseling and Edens (1975) in 
patients undergoing broncoscopy who had been premedicated 
with a relatively high dose of diazepam. Moreover, diaze-
pam, as well as other benzodiazepines not used in clinical 
anesthesia such as chlordiazepoxide, clorazepate and clona-
zepam were effective in reducing stress-induced elevations 
in plasma corticosteriod levels in rats (Le Fur et al., 
1979). On the other hand, in the previously discussed Mel-
sam et al. study (1976) in which diazepam was shown to 
reduce urinary catecholamine excretion in patients with 
acute myocardial infarction, no effect of diazepam on plasma 
cortisol levels was noted. However, in this study, cortisol 
levels were not elevated in the patients who did not receive 
diazepam. Thus, there is evidence to suggest that when 
stress-induced elevations in cortisol occur, these rises can 
be attenuated by benzodiazepine pretreatment. 
Effects of Benzodiazepines on Plasma Renin Activity 
The role of diazepam in counteracting stress-induced 
elevations with regard to plasma renin activity has not been 
widely studied. Lappas et al. (1981) found that cardiac 
surgery patients had elevations in plasma renin activity 
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following fentanyl-diazepam anesthesia and these elevations 
were maintained following surgical stimulation. These 
results suggest that diazepam is ineffective in counteract-
ing a stress-induced increase in plasma renin activity. 
However, because there was no drug-free control group it is 
difficult to interpret these results. Although diazepam 
does not appear to attenuate plasma renin activity, the pre-
cise role of diazepam in plasma renin activity has not been 
determined. 
Summary 
Diazepam has been shown to attenuate, but not abolish, 
stress-induced elevations in plasma catecholamines and cor-
tisol. There are no reports of a benzodiazepine attenuation 
of plasma renin activity. Because a diazepam-free control 
group was not used in many studies, the results are diffi-
cult to interpret and additional studies are needed to clar-
ify confusing data. 
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The Purpose of This Study 
The present animal study will investigate three benzo-
diazepines that are used in clinical anesthesia. Their 
effects on plasma catecholamines, cortisol and renin activ-
ity following drug-induced hypotension and surgical trauma 
will be determined. More specifically, this study will: 
1. Stress an anesthetized dog by drug-induced hypotension 
or surgical trauma and then simultaneously examine 
changes in hemodynamic variables (MAP, HR, CI, RAP, 
SVRI, Wedge, LVSWI - see Methods for detailed explana-
tion of these hemodynamic variables) and changes in 
plasma catecholamines, cortisol and renin activity. 
2. Compare the abilities of diazepam, lorazepam, and the 
investigational benzodiazepine midazolam, to attenuate 
hypotension-induced elevations in plasma catecholamines, 
cortisol, and renin activity. 
3. Investigate the ability of midazolam to attenuate sur-
gery-induced elevations in plasma catecholamines, corti-
sol and renin activity. 
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4. Examine the ability of midazolam to attentuate hypoten-
sion-induced elevations in plasma catecholamines and 
cortisol over a time course similar to that seen in many 
clinical situations. 
This study will provide the knowledge of how diazepam, lor-
azepam, and midazolam influence hormonal responses in ani-
mals subjected to hypotensive and surgical stresses. It is 
anticipated that these results will provide a basis for 
future patient studies involving these drugs. 
CHAPTER II 
METHODS 
General Procedures 
Subjects 
Male mongrel dogs weighing 13-18 kg were used in this 
study, which was approved by the Institutional Committee on 
Animal Care. The animals were individually housed and cared 
for at the Loyola University Animal Research Facility. 
Except for Experiment III, each animal was used in two 
experiments. After participating in one experiment, the 
animals were returned to the animal research facility and 
allowed to recuperate before being used a second time. The 
dogs were killed while anesthetized with a lethal injection 
of potassium chloride upon completion of the second experi-
ment. 
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Procedures 
In order to minimize presurgical stress due to trans-
port, the dogs were brought to the laboratory one hour prior 
to surgery. The dogs were not exposed to the laboratory or 
surgical team prior to their first experimental session. 
Unconsciousness was induced with a 2% solution of sodium 
thiopental (Pentothal), 20.0 mg/kg, which was injected into 
a Butterfly catheter placed in the cephalic vein. Following 
induction, the dogs were intubated using a cuffed endotra-
cheal tube and mechanically ventilated with 100% oxygen. 
Anesthesia was maintained at 1.3 MAC (MAC refers to the min-
imum alveolar concentration of an anesthetic necessary to 
prevent movement to skin incision in 50% of subjects) using 
nitrous oxide-oxygen (1:2) and 2% enflurane (Ethrane). 
Depth of anesthesia was estimated by monitoring standard 
clinical signs of anesthesia such as respiratory pattern, 
eyelid and conjunctival reflexes, pupil size, blood pressure 
and heart rate (Cohen, 1975). Blood anesthesia levels were 
periodically measured using gas chromatography. Standard 
electrocardiogram (ECG) needle electrodes were positioned on 
the dogs so that the Lead II ECG could be continuously moni-
tored on an oscilloscope. 
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Percutaneous cannulas were placed in both femoral 
arteries. Arterial blood pressure was continuously measured 
via one of the cannulas, and arterial blood samples were 
drawn from the other cannula. A urinary catheter was 
inserted so that urine output could be monitored. To main-
tain hydration, lactated Ringer's solution was dripped 
through the Butterfly cannula at a rate of 5 drops/minute. 
Cardiac and pulmonary hemodynamics were monitored 
using a dog Swan-Canz catheter (Edwards Laboratories No. 
93A-095-7F). The frequency of the commercially purchased 
arterial, central venous and pulmonary artery pressure lines 
was measured in this laboratory, and each was recorded as 25 
Hz. The Swan-Canz catheter was inserted into the right 
external jugular vein with the aid of a Cordis introducer. 
The balloon-inflated catheter tip was advanced through the 
right atrium, and right ventricle and advanced until it 
wedged in a branch of the pulmonary artery. Correct place-
ment of the catheter tip was confirmed from pulmonary artery 
pressure tracings. A thermistor near the tip of the Swan-
Ganz catheter was used to measure pulmonary artery blood 
temperature. 
Arterial blood samples were drawn throughout the 
experiment to monitor blood gases. Blood gases including 
pH, arterial oxygen tension and arterial carbon dioxide were 
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measured using a No.165 Corning pH Blood Gas Analyzer, and 
hematocrit was measured using micro hematocrit capillary 
tubes. Respiration was adjusted to maintain arterial carbon 
dioxide at 35-40 mm Hg and pH at approximately 7.4. 
After the experimental set-up was completed and the 
dog's heart rate, blood pressure and blood carbon dioxide 
levels were stable, the dog was maintained on anesthesia for 
one hour. Following this one-hour period, the hypotensive 
or surgical stress was initiated. 
Experimental Design 
This study, which was conducted in enflurane-nitrous 
oxide anesthetized dogs, consisted of three experiments. The 
first experiment was undertaken to investigate changes in 
plasma epinephrine, norepinephrine, cortisol and renin 
activity resulting from nitroprusside-induced hypotension in 
anesthetized dogs. The effectiveness of acute intravenous 
injections of diazepam, lorazepam or midazolam in inhibiting 
these responses was also investigated in this experiment. 
The second experiment investigated the ability of 
midazolam to block the hypotension-induced increases in 
plasma epinephrine, norepinephrine and cortisol when midaz-
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olam was administered prior to the administration of anes-
thesia. 
The third experiment consisted of two parts. In the 
first part, changes in plasma epinephrine, norepinephrine, 
cortisol and renin activity which resulted from a thoraco-
tomy and rib spread were determined. In the second part, 
the ability of an acute injection of midazolam to blunt 
these responses was investigated. 
Forty-two dogs were used in this study. Four groups 
of six dogs were used in the first experiment, one group of 
six was used in the second experiment and two groups of six 
were used in the third experiment. 
The experimental sessions began at approximately 10:00 
a.m. The animals were stablized on anesthesia by 11:00 a.m. 
The drug-induced hypotension or thoracotomy procedures were 
then initiated at approximately 12:00 p.m. 
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Experiment I. Effects of Diazepam, Lorazepam and 
Midazolam 
Elevations 
on 
in 
Nitroprusside-Induced 
Plasma Epinephrine, 
Norepinephrine, Cortisol and Renin 
Activity 
Experiment I (a). In Experiment I (a) the effects of 
nitroprusside-induced hypotension on plasma catecholamines, 
cortisol and renin activity were determined. The results of 
this experiment then served as the control with which the 
results from Experiments I(b), I(c), I(d) and II could be 
compared. 
The general procedures outlined above were followed. 
After the one hour period of anesthesia, mean arterial blood 
pressure was dropped by 30% by infusing 0.01% sodium nitro-
prusside (Nipride) into the cephalic vein. Blood pressure 
was stabilized at this lower level (usually within 7 min-
utes), and the hypotension was continued for 20 minutes. 
The nitroprusside infusion was then terminated and blood 
pressure allowed to return to prestress levels. 
In order to measure plasma catecholamines, cortisol 
and renin activity, 18-ml blood samples were drawn at the 
following intervals: (1) immediately before the hypotensive 
stress (prestress control); (2-4) 2, 10 and 20 minutes after 
stable hypotension was achieved; and (5) 20 minutes after 
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blood pressure return~d to prestress levels following the 
offset of the hypotensive stress. Thus, a total of approxi-
mately 90 mls of blood was drawn during each experimental 
session for subsequent assay. Each blood volume removed was 
replaced with saline. In all experiments, the blood was 
immediately placed in an ice bath and then processed accord-
ing to assay procedures (see p. 53-57) or frozen for later 
assay. Hemodynamic measurements including SAP, DAP, MAP, 
PCWP, CO and HR (see pages 58-63 for a complete description) 
were also taken at intervals 1-5. 
Experiment /(b). In Experiment I(b) the effects of 
diazepam on the responses to a hypotensive stress were exam-
ined. The procedure was the same as that described in 
Experiment I (a), except that diazepam, 0. 4 mg/kg i. v., was 
administered following the withdrawal of the prestress con-
trol blood sample. 
Experiment I (c). In experiment I(c) the effects of 
midazolam on the response to a hypotensive stress were exam-
ined. The procedure was the same as that described in 
Experiment I(b), except that midazolam, 0.2 mg/kg i.v., was 
administered instead of diazepam. 
Experiment I (d). In experiment I (d) the effects of 
lorazepam, a benzodiazepine with a prolonged onset of 
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action, on the responses to a hypotensive stress were exam-
ined. The procedure was the same as that described in 
Experiment I(b), except that because of the delayed onset of 
action of lorazepam, the nitroprusside infusion was started 
30 minutes after the lorazepam (.07 mg/kg i.v.) injection. 
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Experiment II. The Effects of Midazolam Given 1-1/2 
Hours Prior to the Onset of a Hypo-
tensive Stress on Plasma Concentra-
tions of Epinephrine, Norepinephrine 
and Cortisol. 
In this experiment, midazolam, 0. 2 mg/kg iv., was 
slowly administered to awake, unanesthetized animals. This 
procedure was done to determine whether the effects of 
midazolam on the responses to a hypotensive sress would con-
tinue over a time span similar to that of many clinical pro-
cedures. The protocol outlined in Experiment I(a) was fol-
lowed, except that midazolam was administered 10 minutes 
before the induction of anesthes-ia. Because the results of 
Experiment I indicated that midazolam does not block hypo-
tension-induced elevations in plasma renin activity, the 
plasma in this experiment was assayed only for catecholamine 
and cortisol levels. The catecholamine and cortisol data 
obtained from Experiment I(a) served as a basis for compari-
son. 
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Experiment Ill. The Effects of Midazolam on Plasma 
Epinephrine, Norepinephrine, Corti-
sol and Renin Activity Following 
Surgical Trauma 
In Experiment III(a) the effects of surgical stress on 
plasma catecholamines, cortisol and renin activity were 
investigated. The results from this experiment then served 
as the control with which the results from Experiment III(b) 
could be compared. 
Experiment /1/(a). In this experiment the general proce-
dures were the same as previously described. However, the 
animals in this experiment were subjected to a surgical 
rather than hypotensive stress. After one hour of stable 
anesthesia, thoracotomies were performed on the dogs. The 
thoracotomies were performed by first making a skin incision 
on the right side of the chest to expose the 5th and 6th 
ribs. The pleural cavity was then entered between these 
ribs and the intrarib distance at peak inspiration measured. 
A self-maintaining retractor was placed between the 5th and 
6th ribs at a position 90-110 mm from the sternal midline 
and spread so that the distance between these ribs was 4 
times the intrarib distance, ranging 65 to 75 mm. (This 
distance was found to be the maximum rib spread that occur-
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red without rib breakage.) Final placement of the retractor 
took approximately 5 minutes from skin incision. The 
retractor remained in place for 20 minutes and then was 
removed. 
Blood samples for chemical assays (approximately 18 
mls) were drawn from the femoral artery cannula at the fol-
lowing intervals: (1) immediately before skin incision 
(prestress control); (2-5), 2, 5, 10 and 20 minutes after 
placement of the retractor; and (6) 20 minutes after removal 
of the retractor. Hemodynamic measurements were also taken 
at sample intervals 1-5, and heart rate and blood pressure 
were measured at one minute intervals from the time of skin 
incision to placement of the retractor. 
Experiment 11/(b). In Experiment III(b), the effects 
of midazolam on the stimulatory response to surgical trauma 
were investigated. The procedure described for Experiment 
III (a) was followed, except that 2 minutes prior to skin 
incision, midazolam, 0. 2 mg/kg i. v., was injected into the 
cephalic vein. 
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Biochemical Determinations 
Catecholamine Fluorometric Assay 
Plasma epinephrine and norepinephrine concentrations 
were determined using a modification of the method of Vend-
salu (1960) and Haggendal (1963). Thirteen milliliters of 
the total arterial blood withdrawn at each time period were 
collected in heparinized centrifuge tubes for this assay. 
The heparinized blood was centrifuged for 10 minutes at 
4, 000 RPM at a temperature of +4 °C. The plasma was then 
removed, measured for volume, and approximately 0.1 ml of a 
solution containing 10% EDTA and 2% ascorbic acid in 4.0 N 
perchloric acid was added to every ml. of plasma to depro-
teinize the plasma and stabilize the catecholamines. The 
treated plasma was refrigerated for 30 minutes at +6°C and 
then centrifuged for 20 minutes. The acidified supernatant 
was collected and the protein pellet re-extracted with 0.4 N 
PCA. After centrifugation the two supernatants were com-
bined. The acidified deproteinized plasma containing epi-
nephrine and norepinephrine were then stored at -20°C. 
Purification and isolation of epinephrine and norepi-
nephrine were accomplished using ion-exchange column chroma-
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tography as describeq by Glisson (1971). This technique 
involved thawing the acidified deproteinized plasma and then 
passing the plasma sample through an ion exchange column 
buffered to a pH of 6.5. The resin column was washed with 
water followed by 1. SN hydrochloric acid to elute epineph-
rine and norepinephrine from the resin column. The acid 
eluate, containing epinephrine and norepinephrine, was col-
lected and stored at -20°C until the samples were thawed for 
further processing (<48 hrs.). Epinephrine and norepineph-
rine were quantified upon conversion of the amines to their 
respective fluorophores using the trihydroxyindole technique 
(Glisson et al., 1972). Developed fluorescence was then 
measured at 405/505 and 455/505 nM in and Aminco-Bowman 
spectrophotofluorometer equipped with an ellipsoidal mirror 
condensing system. Plasma epinephrine and norepinephrine 
concentrations were calculated from a standard curve and 
expressed as ng/ml (cf., Appendix B). Maximum sensitivity 
of this system was determined to be plus or minus . 45 
ng/ml. Using a minimum 5.0 ml plasma sample provided suffi-
cient concentration to quantify. Approximately 80% recovery 
of epinephrine and norepinephrine have been found in this 
laboratory. Reported values are uncorrected. The between-
assay coefficient of variation was approximately 10%. 
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Renin Activity Radioimmunoassay 
Plasma renin activity was assayed in duplicate using 
the Becton Dickinson Renin Activity Radioimmunoassay Kit 
(us!), as modified from the method of Haber et al. (1969). 
According to this procedure, 5-ml samples of arterial blood 
were collected in prechilled Vacutainer tubes containing 
sufficient disodium EDTA to achieve a final concentration of 
1.4 mg/ml. The plasma was immediately separated in a 
refrigerated centrifuge. One milliliter of the cold plasma 
was then transferred to a polystyrene test tube and stored 
at -20°C until the radioimmunoassay was performed. The 
remainder of the plasma was also stored at -20°C for later 
use in the cortisol radioimmunoassay. 
To perform the radioimmunoassay, the plasma was thawed 
and buffered by Tris Chloride to pH 7.4. 
a-hydroxyquinoline solution were added 
Dimercaprol and 
to the buffered 
plasma to inhibit the transformation of angiotensin I to 
angiotensin II and breakdown products. Angiotensin I was 
then generated by placing treated plasma in a heated bath 
(37°C) for 3 hours. A blank was made by stimultaneously 
storing the other half of the treated plasma in an ice bath. 
Following Angiotensin I generation, the assay proce-
dure was initiated. The assay involved adding a constant 
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amount of angiotensin 125 1 tracer and angiotensin antiserum 
in tris acetate buffer to test tubes containing either the 
plasma samples or angiotensin I standards. The tubes were 
then incubated 20-24 hours at 2-8°C. After incubation, sep-
aration of the bound and free angiotensin was achieved rap-
idly by contact with dextran-coated charcoal. The antibody-
bound 12 5 I in the supernatant solution was then decanted 
into a numbered tube and counted using a Packard Liquid 
Scintillation Spectrometer adjusted for the measurement of 
125 I. A standard curve was plotted and the concentration of 
angiotensin I in the plasma was determined from the standard 
curve and expressed as ng/ml/hr of angiotensin I generated 
(cf., Appendix B). The sensitivity of this assay was shown 
to be 0.14 ng angiotensin I/ml plasma, and the precision of 
the assay was shown by a within-assay coefficient of varia-
tion (C.V.) of 2.9% and between-assay C.V. of 8.5% 
Cortisol Radioimmunoassay 
Plasma cortisol concentrations were measured in dupli-
cate using the Amerlex Cortisol RIA Kit. The plasma sam-
ples used in this assay were collected according to the pro-
cedures described for the renin activity radioimmunoassay. 
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In this assay, cortisol 12 5 I and cortisol antiserum 
were pipetted into tubes containing 50 mel aliquots of the 
standard, control or experimental serum samples. The tubes 
were incubated in a 37°C water bath for one hour and centri-
fuged for 15 minutes. The supernatant was counted in a 
Packard Liquid Scintillation Spectrometer. Finally, a stan-
dard curve was constructed, and the concentration of corti-
sol in the plasma was determined from the curve and 
expressed as meg cortisol/100 ml plasma (cf., Appendix B). 
The sensitivity of this assay was shown to be 0.1 meg corti-
sol/100 ml plasma, and the precision of the assay was shown 
by a within-assay C. V. of 5. 7% and between-assay C. V. of 
8.9%. 
58 
Hemodynamic Monitoring 
Hemodynamic monitoring provides direct measurement of 
cardiac performance. From these measurements, derived indi-
ces can be calculated. The raw and derived data then were 
used to evaluate cardiovascular function. 
Direct Physiological Measurements 
Cardiovascular Pressures 
The femoral artery catheter was used to measure sys-
tolic arterial pressure (SAP) and diastolic arterial pres-
sure (DAP). From these pressures the mean arterial pressure 
(MAP) was calculated as: 
MAP = (DAP + 1/3(SAP-DAP)) 
The mean arterial pressure is the average pressure during a 
given cardiac cycle that exists in the aorta and its major 
branches (Berne and Levy, 1977). Mean arterial pressure is 
the average pressure tending to push blood through the sys-
temic circulatory system (Guyton, 1976). This, as well as 
other cardiovascular pressures, are expressed in mm Hg. 
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The Swan-Ganz cathether was used to obtain pulmonary 
capillary wedge pressure (PCWP or wedge), pulmonary artery 
systolic pressure (PASP), pulmonary artery diastolic pres-
sure (PADP) and right atrial pressure (RAP). The wedge 
pressure is the most useful of these pressures because it 
reflects left ventricular end diastolic pressure (Gilbert 
and Hew, 1979; Kaplan, 1979). Consequently, an elevated 
wedge pressure usually indicates an acute fluid overload or 
a decrease in myocardial performance (Roizen et al., 1981). 
Right atrial pressure is used to evaluate right ventricular 
function. The pulmonary pressures provide data on pulmonary 
vascular resistance. 
Cardiac Output 
Cardiac output (CO) is the volume of blood pumped by 
the left ventricle into the aorta per unit time, typically 
per minute. Under normal circumstances, the major factor 
determining the cardiac output is venous return, which is 
the amount of blood that is pumped into the heart each min-
ute. When the arterial pressure remains normal and the 
heart is healthy, cardiac output is controlled by the needs 
of local tissues throughout the body (Guyton, 1976). It 
should be noted that during anesthesia, control of cardiac 
output circulatory dynamics differs from the non-anesthetic 
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state, reflecting a balance of depressant actions by anes-
thetic agents and compensating reflexes (Hickey and Eger, 
1981, Kaplan, 1981). 
Two major determinants of venous return and cardiac 
output are arterial pressure and total peripheral resistance 
(Guyton, 1976). Arterial pressure is controlled by three 
groups of mechanisms that differ in their onset of action. 
The first group consists of short term mechanisms including 
(1) the hormonal norepinephrine - epinephrine vasoconstric-
tor mechanism, and (2) nervous mechanisms such as the baro-
receptor mechanism, the chemoreceptor mechanism and the CNS 
ischemic feedback mechanism. 
The baroreceptor mechanism is probably the best known 
of the short-term nervous mechanisms for regulating arterial 
pressure (Guyton, 1976). Baroreceptors are nerve endings 
lying in the walls of arteries and are especially abundant 
in the walls of the internal carotid arteries and the walls 
of the aortic arch. Baroreceptors are stimulated when 
stretched and respond rapidly to changes in arterial pres-
sure. They respond much more to a rising pressure than a 
falling pressure. Impulses from the baroreceptors inhibit 
the vasoconstrictor center of the medulla and excite the 
vagal center. The net effects, which are mediated through 
sympathetic and parasympathetic nerves, are vasodilation 
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throughout the peripheral circulation and decreased cardiac 
output and strength of contraction. 
The short-term mechanisms begin to act within seconds 
whenever any disturbance attempts to change the arterial 
pressure to a value higher or lower than its normal level. 
Baroreceptors are probably of no importance in long-term 
regulation of arterial pressure since they adapt in one to 
two days to whatever pressure level they are exposed. 
The intermediate-term pressure control mechanisms are 
represented by stress-relaxation of the vasculature, the 
renin-angiotensin-vasoconstrictor mechanisms and the capil-
lary fluid shift mechanism. These intermediate pressure 
control mechanisms become activated when a disturbance which 
tends to alter arterial pressure continues for minutes or 
hours. 
The long-term arterial pressure control mechanisms are 
represented by the renal-body fluid pressure control system 
and the aldosterone control system. These long term pres-
sure control mechanisms are slow to act, usually requiring 
that the disturbance altering arterial pressure continue for 
hours before they become effective. 
The second major determinant of cardiac output is 
total peripheral resistance, also known as systemic vascular 
resistance. Resistance refers to the impediment to blood 
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flow in a vessel, and total peripheral resistance is the 
resistance of the entire systemic circulation. The resis-
tance of a vessel is directly proportional to the blood vis-
cosity and length of the vessel, but inversely proportional 
to the fourth power of the radius of the vessel (Guyton, 
1976). 
In this study, cardiac output was measured by thermo-
dilution using a Swan-Canz catheter and an Edwards Labora-
tory cardiac output computer. The method involved injecting 
a 3-ml 0°C 5% dextrose-in-water solution into the catheter. 
The cold solution then flowed into the right atrium, under-
went rapid mixing, and the resultant temperature change was 
detected by a thermistor that was positioned near the tip of 
the Swan-Canz cathether. Cardiac output, which is 
inversely proportional to the integral temperature change, 
was calculated by the cardiac output computer and expressed 
in L/min. Cardiac output was taken as the mean of three 
sequential cardiac output measurements within 10% of each 
other. Cardiac output measurements obtained with the 
Swan-Canz catheter were previously shown in this labora-
tory to correlate well with cardiac measurements obtained 
using indocyanine (cardiogreen). 
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Heart Rate 
Heart rate (HR), expressed in beats/minute, was meas-
ured using a standard Lead II electrocardiogram (ECG). The 
central and autonomic nervous systems are the main factors 
affecting heart rate (Kaplan, 1979); that is, heart rate is 
increased by sympathetic activity and parasympathetic with-
drawal, and decreased by parasympathetic activity. 
Derived Indices 
Using directly measured hemodynamic data, parameters 
can be calculated that provide important additional insights 
into cardiovascular function. In order to compare the hemo-
dynamic profiles of animals of different body sizes, the 
variables are corrected by dividing by the body surface area 
(BSA). Such corrected parameters are expressed as indices. 
Cardiac Index 
Cardiac index (CI), expressed in L*min- 1*M- 2 , was cal-
culated as: 
CI = (CO/BSA) 
Systemic Vascular Resistance 
Index 
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Systemic vascular resistance index (SVRI) is a measure 
of peripheral vascular constriction of the small arteries or 
arterioles. It is an indicator of the resistance that the 
heart must overcome to pump blood through the systemic cir-
culation. Vasodilator drugs such as nitroprusside can 
decrease the systemic vascular resistance. Catecholamines 
have differential effects on systemic vascular resistance; 
that is, norepinephrine tends to increase it, isoproterenol 
tends to decrease it, and the effects of epinephrine vary 
yth dosage and target organ (Innes and Nickerson, 1975). 
Systemic vascular resistance index, 
SVRI = (((MAP-RAP)*79.9)/CI) 
Left Ventricular Stroke Work 
Index 
expressed in 
Left ventricular stroke work index (LVSWI or stroke 
work index) is a measure of the amount of work performed by 
the heart. A depressed stroke work index suggests that the 
pumping ability of the heart is weakened. An elevated 
stroke work index, on the other hand, may reflect a compen-
satory mechanism for a condition requiring an abnormally 
high contractile force (Brantigan, 1982). An elevated 
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stroke work index is also an indication that an increased 
oxygen demand is being placed on the heart. Stroke work 
index depends in part on stroke index (SI). Stroke index is 
the amount of blood pumped per heartbeat, expressed in 
ml•'<M- 2 , and calculated as: 
SI = (CI/HR) 
Stroke work index, in g*M*M- 2 , is then calculated as: 
LVSWI = ((13.6(MAP-PCWP))*SI) 
Although all of the hemodynamic variables which have 
been described were collected during the course of the 
experiments, only selected variables exhibiting noteworthy 
changes will be presented and discussed throughout this 
paper. 
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Data Analysis 
The data were analyzed using an IBM 3033-S computer 
system and the Statistical Analysis System (Helwig and Coun-
cil, 1979) computing package. Initially a split-plot analy-
sis of variance CANOVA) was performed on the data. When 
significant results were obtained from the ANOVA, further 
testing was done. The effects of stress within individual 
drug groups was assessed using Duncan 1 s new multiple range 
test. A comparison of the effects of different drugs at a 
given time period was made using the nonpaired Student 1 s 
t-test. In all experiments in the present study, a prob-
ability of less than . 05 was considered statistically sig-
nificant. 
The Analysis of Variance 
Indications 
When an experiment involves more than two treatment 
means, the first statistical test should be an ANOVA to rule 
out the possibility that any observed differences between 
means are merely due to sampling fluctuations (Wallenstein 
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et al., 1980; Zivin and Bartko, 1976; Arkin and Colton, 
1970). If the ANOVA indicates that differences probably 
exist, then the investigator may proceed with further test-
ing to determine which pairs of means differ from each 
other. 
Basic Concepts 
The ANOVA tests the hypothesis that all treatment 
means are equal. In its simplest form, ANOVA accomplishes 
this by comparing two different estimates of population var-
iances. (Variance is simply the square of a standard devia-
tion.) One variance, based on differences among the treat-
ment means, is referred to as the between-group variance. 
The other variance, based on the variation of values within 
each treatment is called the within-group variance. If the 
initial hypothesis is correct and all treatment means are 
equal, then these two estimates of the population variance 
should be similar. In fact, they should differ only by an 
amount equal to that which might arise from sampling fluctu-
ations. However, if the between-group variance is signifi-
cantly greater than the within-group variance, then the dif-
ferences among the treatment means are not due to sampling 
fluctuations alone, but rather reflect a true difference. 
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The F -test is used to compare the between-group and 
within-group variances. In this test, the variances are 
first corrected for differences in degrees of freedom by 
dividing the between-group and within-group variances by 
their respective degrees of freedom. The calculated values 
are then referred to as mean square between group (MSBG) and 
mean square within group (MSWG). The F-ratio (the ratio of 
two independent chi-square variables, each divided by its 
degrees of freedom) is then calculated as: 
F = (MSBG/MSWG) 
The largest value of F that might occur due to sampling 
fluctuations at a given significance level can be found in a 
table of F -values (see Kirk, 1968). If the calculated F 
exceeds this value, then it may be said that the group means 
differ significantly. 
Assumptions 
The ANOVA assumes that the measurements are obtained 
by random sampling from normally distributed populations of 
equal variances. According to Kirk (1968), populations 
showing moderate departures from a normal distribution and 
having unequal variances will have little effect on the 
F-test. It is most important, however, that the measure-
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ments are obtained by'random sampling. Failure to meet the 
assumptions of any statistical test will affect both the 
significance level and the sensitivity of a test. The ANOVA 
is considered very robust with respect to most assumptions. 
Design 
The design used in this study has been referred to as 
8 split-plot design by Kirk (1968) and as a two-factor 
experiment with repeated measures by Winer (1962). A 
split-plot design is really a composite of two simpler 
designs -- one design in which each subject receives only 
one level of a treatment and a second design in which each 
subject receives all levels of a treatment. Because each 
dog received only one drug, while being tested at all time 
periods, this model is consistent with the description of a 
split-plot design. 
From the analysis of variance, each variable under 
statistical consideration (such as plasma catecholamine lev-
els) can be tested for a drug effect, a time effect, and a 
drug*time interaction. In the present experiments, a sig-
nificant drug effect suggests an overall, nontime-related 
difference between two or more drug treatment groups (diaze-
pam, midazolam, lorazepam or saline treated animals). A 
significant time effect suggests an overall, nondrug-re-
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lated, difference between two or more time periods. A sig-
nificant drug*time interaction would suggest that two or 
more drug groups behaved differently over different time 
periods and consequently did not respond uniformly over the 
course of the experiment. 
Duncan's New Multiple Range Test 
After ANOVA indicates that there are significant dif-
ferences among various time periods, the next step is to 
determine which pairs of means are different. Using Dun-
can's new multiple range test, all pairwise comparisons of 
means can be simultaneously obtained. The Duncan test, 
fully described by Kirk (1968), first requires ranking the 
means according to size and then calculating the differences 
between the means. For a pair of means to be considered 
significantly different, the difference between the two 
means must exceed a value determined using a table of Duncan 
values (see Kirk, 1968). 
A major advantage of Duncan's new multiple range test 
is that the probability level (alpha) is spread across all 
pairwise comparisons, thus avoiding the increase in alpha 
that occurs with multiple paired-t comparisons. Also, Dun-
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can's test is less conservative than many other tests since 
it will show a significant difference between means more 
often than most other acceptable multiple comparison proce-
dures. 
Nonpaired Student's T-Test 
When the ANOVA shows that drug groups differ from each 
other a nonpaired Student's t-Test can be used to determine 
which groups differ from other drug groups at any given time 
period. In this test, two means are compared by calculating 
a t-statistic (the t-statistic equals the ratio of the dif-
ference between the two means divided by the standard error 
of the difference between the means). When the t-statistic 
exceeds a value determined by the degrees of freedom and 
specified in a table oft-values (see Kirk, 1968), the means 
are considered statistically different. All comparisons in 
this study were made using two-tailed tests. That is, the 
probability level (alpha) was equally divided between the 
two tails of the t-distribution. 
Control Animals 
CHAPTER III 
RESULTS 
Experiment I 
Hemodynamic Measurements 
The hemodynamic response of control animals to the 
nitroprusside-induced hypotension is shown in Table 1. In 
this group of animals, blood pressure during the nitroprus-
side infusion was maintained close to the targeted 30% 
decrease from the prestress control value. Although a 
rebound hypertension was not seen at the 20-minute postinfu-
sion recovery period, some animals did show a slight (within 
10 mm Hg) and transient increase in blood pressure shortly 
after the nitroprusside infusion was terminated. 
Heart rate remained relatively stable throughout the 
hypotensive period. Moderate decreases in heart rate were 
seen after 20 minutes of hypotension and lasted into the 
recovery period. 
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Table 1. Hemodynamic profile of control (saline-treated) 
dogs in response to a nitroprusside-induced 30% decrease in 
mean arterial blood pressure. Abbreviations used are: MAP, 
mean arterial blood pressure; HR, heart rate; CI, cardiac 
index; RAP, right atrial pressure; SVRI, systemic vascular 
resistance index; Wedge, pulmonary capillary wedge pressure; 
and LVSWI, left ventricular stroke work index. Values rep-
resent means plus or minus SEM. The asterisk indicates a 
significant difference between the indicated value and its 
corresponding prestress control value. 
TABLE 1 
HEMODYNAMIC PROFILE OF CONTROL DOGS: HYPOTENSION 
Hz:Eotension 
20 Min 
Prestress Post-
Control 2 Min 10 Min 20 Min Recovery 
MAP 92+4 61+3* 64+4* 63+3* 93+6 
(rnrn Hg) 
HR 118+6 117+3 116+5 110+4 110+6 
(rnin-1) -
CI 4.2+0.3 3.0+0.3* 3.2+0.3* 2.9+0.2* 3.6+0.3* (L ·min -1.M- 2) -
RAP 2.8+0.7 2.4+0.6 2.3+0.5 2.4+0.6 3.1+0.8 
- -(rnrn Hg) 
SVRI 1744+169 1623+212 1535+146 1653+127 2008+155* 
(dyne·sec·crn-5·M2) - -
Wedge 6.0+0.7 5.2+0.5 5.7+0.5 5.8+0.6 6.2+0.5 
(rnrn Hg) 
18+1* 22+2* 21+2* 40+5 ...... LVSWI 41+4 .j:-
(grn · M ·M- 2) 
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Cardiac index was significantly decreased throughout 
the hypotensive period. During the recovery period, car-
diac index increased, but remained significantly lower than 
the prestress control value. 
Systemic vascular resistance index decreased slightly 
and insignificantly during the hypotensive period. The max-
imal decrease (12%) occurred in the first 10-minutes of the 
hypotensive period. A statistically significant increase in 
systemic vascular resistance index was seen during the 
recovery period; however, this value was not greatly ele-
vated above the prestress control value. 
Changes in stroke work index were similar to changes 
in blood pressure, since significant decreases were seen 
only during the hypotensive period. During the recovery 
period, stroke work index increased to the prestress control 
level. 
Right atrial and wedge pressures were within the nor-
mal range during the hypotensive and recovery periods. 
Benzodiazepine-Treated 
Animals 
The hemodynamic response of the dogs pretreated with 
diazepam, lorazepam or midazolam prior to the hypotensive 
stress are shown in Tables 2-4. Prestress hemodynamic 
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Table 2. Hemodynamic profile of diazepam-treated dogs in 
response to a nitroprusside-induced 30% decrease in mean 
arterial blood pressure. Abbreviations used are: MAP, mean 
arterial blood pressure; HR, heart rate; CI, cardiac index; 
RAP, right atrial pressure; SVRI, systemic vascular resis-
tance index; Wedge, pulmonary capillary wedge pressure; and 
LVSWI, left ventricular stroke work index. Values represent 
means plus or minus SEM. The asterisk indicates a signifi-
cant difference between the indicated value and its corre-
sponding prestress control value. 
TABLE 2 
HEMODYNAMIC PROFILE OF DIAZEPAM DOGS: HYPOTENSION 
H:n~o tens ion 
20 Min 
Prestress Post-
Control 2 Min 10 Min 20 Min Recoverz: 
MAP 94+4 66+3* 64+3* 68+3* 98+5 
(mm Hg) 
HR 111+6 115+12 114+11 112+9 107+7 
(min-1) 
CI 3.7+0.4 3.0+0.3* 3.3+0.3 3.4+0.4 3.3+0.4* 
(L ·min -1. M- 2) - - -
RAP 2.4+0.8 2.1+0.5 3.1+1.1 2.6+0.8 3.2+1.1 
- -(mm Hg) 
SVRI 1919+282 1683+252 1417+169* 1617+297* 2183+306 
(dyne·sec·cm-5.M2) - -
Wedge 5.2+0.7 5.2+0.7 5.2+0.7 5.2+0.9 5.2+0.6 
-(mm Hg) 
LVSWI 
(gm·M·M-2) 
39+3 21+2* 23+2* 24+2* 38+5 "'--"'--
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Table 3. Hemodynamic profile of lorazepam-treated dogs in 
response to a nitroprusside-induced 30% decrease in mean 
arterial blood pressure. Abbreviations used are: MAP, mean 
arterial blood pressure; HR, heart rate; CI, cardiac index; 
RAP, right atrial pressure; SVRI, systemic vascular res is-
tance index; Wedge, pulmonary capillary wedge pressure; and 
LVSWI, left ventricular stroke work index. Values represent 
means plus or minus SEM. The asterisk indicates a signifi-
cant difference between the indicated value and its corre-
spending prestress control value. 
TABLE 3 
HEMODYNAMIC PROFILE OF LORAZEPAM DOGS: HYPOTENSION 
Hn~otens ion 
20 Min 
Prestress Post-
Control 2 Min 10 Min 20 Min Recoverr 
MAP 87+3 62+3* 62+3* 61+3* 90+3 
(mm Hg) 
HR 107+6 117+13 114+12 117+9 100+3 
(min-1) -
CI 4.5+0.3 3.8+0.4 3.8+0.5 4.1+0.7 4.0+0.3 
(L·min-l.M-2) - -
RAP 3.2+0.9 2.9+0.8 3.7+1.1 3,8+1.2 3. 7+1.0 
-(mm Hg) 
SVRI 1486+64 1332+179 1277+142 1229+195 1769+148 
(dyne·sec·cm-5·M2) - -
Wedge 4.9+1.1 5.0+1.0 4.8+0.9 5.8+1.1 6.3+1.4* 
- -(mm Hg) 
'-J 
LVSWI 49+7 27+5* 28+6* 28+6* 45+5 1.0 
(gm ·M·M- 2) 
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Table II. Hemodynamic profile of midazolam-treated dogs in 
response to a nitroprusside-induced 30% decrease in mean 
arterial blood pressure. Abbreviations used are: MAP, mean 
arterial blood pressure; HR, heart rate; CI, cardiac index; 
RAP, right atrial pressure; SVRI, systemic vascular res is-
tance index; Wedge, pulmonary capillary wedge pressure; and 
LVSWI, left ventricular stroke work index. Values represent 
means plus or minus SEM. The asterisk indicates a signifi-
cant difference between the indicated value and its corre-
sponding prestress control value. 
TABLE 4 
HEMODYNAMIC PROFILE OF MIDAZOLAM DOGS: HYPOTENSION 
H}:]~otens ion 
20 Min 
Prestress Post-
Control 2 Min 10 Min 20 Min Recoverr 
MAP 96+4 61+4* 62+4* 63+3* 93+4 
(mm Hg) 
HR 114+10 108+9 104+8* 104+9* 98+7* 
(min-1) -
CI 5.5+0.7 4.3+0.5* 4.4+0.5* 3.8+0.5* 4.5+0.5* 
(L·min-1·M-2) -
RAP 4.0+1.1 3.0+1.1* 3.0+1.1* 3.1+1.1* 4.6+1.0 
(mm Hg) -
SVRI 1358+102 1138+126 1101+109* 1299+87 1628+132* 
(dyne·sec·cm-5·M2) -
Wedge 8.5+1.9 7.3+1.5 6.7+1.3 7.3+1.5 8.2+1.4 
- -(mm Hg) 
58+4 29+5* 32+3* 28+4* 52+4 00 LVSWI ~ 
(gm·M·M-2) 
82 
values in these three drug groups were similiar to the con-
trol values. Blood pressure during the hypotensive period 
was maintained at approximately 30% of the prestress control 
level in all of these groups. Heart rate remained rela-
tively stable, with only the midazolam-treated animals show-
ing any significant changes, and the decreases seen in these 
animals were not clinically significant. 
Cardiac index was decreased somewhat during hypoten-
sion in all benzodiazepine groups, but the magnitude of the 
response varied between the groups. The greatest decreases 
in cardiac index were seen in the midazolam group, which 
showed significant decreases throughout the hypotensive and 
recovery periods. In the diazepam group, the decreases in 
cardiac index only reached significance at the 2-minute 
hypotensive period and the recovery period. The lorazepam 
group showed the least amount of change in cardiac index, 
since there were no statistically significant decreases in 
cardiac index in this group. 
Changes in systemic vascular resistance index in the 
benzodiazepine groups were similar to those reported in the 
control group, as only slight decreases were seen during the 
hypotensive and recovery periods. Systemic vascular resis-
tance index appeared to be most stable in the lorazepam 
group because no significant changes were noted at any time 
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period in these animals. The diazepam group, like the lor-
azepam group, did not show a significant elevation in sys-
temic vascular resistance index during the recovery period; 
however, significant decreases were seen after 10 and 20 
minutes of hypotension. Changes in systemic vascular resis-
tance index in the midazolam group were most similar to 
those seen in the control group since a significant decrease 
was recorded both during hypotension (at 10 minutes) and 
after recovery of blood pressure. 
In all three benzodiazepine groups, stroke work index 
followed the same pattern as that shown for the control 
group. There was a significant decrease in stroke work 
index during the hypotensive period. This increase was not 
maintained during the recovery period as stroke work index 
approached prestress control levels at this time. 
Changes in wedge pressure in the benzodiazepine groups 
were similar to changes in wedge pressure in the control 
animals. No satistically significant changes in wedge pres-
sure were seen in any benzodiazepine group during the hypo-
tensive period. In the lor azepam group, however, wedge 
pressure began increasing during the last 10 minutes of the 
hypotensive period, and this increase became statistically 
significant during the recovery period. 
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No significant changes in right atrial pressure were 
seen in either the diazepam or lorazepam groups. However, 
significant decreases in the midazolam group were seen 
throughout the hypotensive period. 
ANOVA 
The two-way analysis of variance of the experimental 
groups showed a significant time effect for all of the hemo-
dynamic variables listed in Tables 1-4. No significant drug 
effect or drug*time interactions, however, were seen for any 
hemodynamic variable. 
Plasma Catecholamine Concentrations 
Control Animals 
Epinephrine. Plasma epinephrine levels were signifi-
cantly elevated throughout the hypotensive period, and these 
elevated levels were sustained during the recovery period 
(Figure 1). Within 2 minutes after stable hypotension was 
achieved, plasma epinephrine levels increased 64% above the 
prestress control level and then did not change markedly 
during the remaining hypotensive period or on recovery. 
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Figure 1. Comparison of plasma epinephrine levels (mean 
plus or minus SEM) before, during and after a 30% decrease 
in mean arterial blood pressure in dogs receiving saline, 
diazepam, lorazepam or midazolam prior to the hypotension. 
Sample periods are: (1) prior to the hypotension (prestress 
control); (2-4) 2, 10 and 20 minutes after stable hypoten-
sion; and (5) 20 minutes after blood pressure returned to 
prestress control levels. The asterisk indicates a signifi-
cant difference (p<.05) between the indicated value and its 
corresponding prestress control value. 
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Norepinephrine. · Plasma norepinephrine levels were 
significantly elevated early in the hypotensive period 
(Figure 2). However, the increases in plasma norepinephrine 
were not nearly so dramatic as those for plasma epinephrine. 
The maximum increase in norepinephrine, occurring 2 minutes 
after stable hypotension, was only 30% of the prestress 
control value. During the remainder of the hypotensive 
period, plasma norepinephrine levels remained close to the 
2-minute value, and on recovery they approached prestress 
control levels. 
Benzodiazepine- Treated 
Animals 
Epinephrine. Pretreatment with either diazepam, lor-
azepam or midazolam attenuated the surge in plasma epineph-
rine that was seen following the hypotensive stress (Figure 
1). The largest effect was seen in the diazepam group at 
the 2-minute hypotensive preiod. At this time, epinephrine 
levels which were increased 64% in the control group were 
only increased 10% in the diazepam group. Furthermore, the 
maximum increase seen in the diazepam group, occurring 20 
minutes into the hypotensive period, was only 16% above the 
prestress control value. Also, by the recovery period epi-
nephrine levels had returned to the prestress control value. 
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Figure 2. Comparison of plasma norepinephrine levels (mean 
plus or minus SEM) before, during and after a 30% decrease 
in mean arterial blood pressure in dogs receiving saline, 
diazepam, lorazepam or midazolam prior to the hypot~nsion. 
Sample periods are: (1) prior to the hypotension (prestress 
control); (2-4) 2, 10 and 20 minutes after stable hypoten-
sian; and (5) 20 minutes after blood pressure returned to 
prestress control levels. The asterisk indicates a signifi-
cant difference (p<.OS) between the indicated value and its 
corresponding prestress control value. 
3 
N 
0 
R 
* * E p 2 
I 
N 
E 
p 
H 
R 1 
I 
N 
E 
I 
N 
c 0 L M c 0 L M c D L M c D L M c 0 L M 
N 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0 I 0 I N A R D N A R D N A R D N A R D N A R 0 G T z A A T z A A T z A A T z A A T z A A I R E z z R E z z R E z z R E z z R E z z 
M 0 p E 0 0 p E 0 0 p E 0 a p E a a p E a 
L L A p L L A p L L A p L L A p L L A p L ()) M A A M A A M A A M A A M A A 1.0 
M M M M M M M M M M 
1 ---i 2 ---i 3 ---f 4 --t 5 ---i 
SAMPLE PERIOD 
90 
Midazolam also attenuated the hypotension-induced rise 
in plasma epinephrine levels. The maximum attenuation in 
plasma epinephrine (15% above the control levels) was seen 
during the 10-minute hypotensive period. At the 2-minute 
hypotensive period, plasma epinephrine levels were 40% 
greater than prestress control levels. However, this 
increase was not statistically significant, presumably due 
to the large amounts of variability in the data. In 
general, after the 2-minute period, plasma epinephrine 
levels fell and remained near prestress control levels 
throughout the hypotensive and recovery periods. 
The results of the lorazepam group are somewhat 
difficult to interpret since the prestress control 
epineprhine level in ths group was significantly lower than 
that in other experimental groups. A review of the events 
that occurred during the lorazepam experiments did not 
reveal a specific cause for the lower prestress control 
value in this group. Lorazepam was given earlier than 
diazepam or midazolam and its action on catecholamines may 
have been in progress. However, it does appear that the 
lorazepam animals responded to the hypotensive stress 
similarly to the other benzodiazepine-treated animals. The 
only significant elevation in plasma epinephrine in this 
group was seen at the 10-minute hypotensive period, and this 
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value was relatively low. Furthermore, like the other 
benzodiazepine groups, on recovery of blood pressure plasma 
epinephrine in the lorazepam group approached prestress 
control levels. 
Norepinephrine. The hypotension-induced rise in 
plasma norepinephrine levels seen in control animals was 
attenuated in all benzodiazepine groups. No significant 
elevations in norepinephrine levels were seen during the 
hypotensive or recovery periods in any benzodiazepine group 
(Figure 2). Not only was the hypotension-induced rise in 
plasma norepinephrine levels attenuated, but a progressive 
decrease in plasma norepinephrine from prestress control 
levels occurred in all three benzodiazepine groups. 
Although the decrease in plasma norepinephrine levels was 
not statistically significant in any benzodiazepine group, 
the fall in plasma norepinephrine is of interest since it 
occurred following 
benzodiazepines. The 
administration of 
largest decrease 
all 
in 
three 
plasma 
norepinephrine (28%) from prestress values was seen in the 
diazepam-treated animals at the 10- and 20-minute 
hypotensive periods. Lorazepam showed a 19% decrease at the 
2-minute hypotensive period, and midazolam showed a 14% 
decrease at the 10-minute hypotensive period that lasted 
through the recovery period. 
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ANOVA 
The analysis of variance of plasma epinephrine levels 
showed both a significant drug and time effect, but the 
drug*time interaction did not prove to be significant. The 
significant drug effect was most likely due to a significant 
difference between the lorazepam animals and other experi-
mental animals, since the other groups did not differ from 
each other with respect to plasma epinephrine levels. 
The analysis of variance performed on plasma norepi-
nephrine levels did not show a significant time effect, 
although a significant drug effect and drug*time interaction 
were revealed. 
Plasma Cortisol Levels 
Control Animals 
Figure 3 shows that following a hypotensive stress, 
plasma cortisol levels began increasing and reached statis-
tical significance by the 10 minute hypotensive period. 
Cortisol levels continued to rise, and by the 20-minute 
hypotensive period they had increased 73% above prestress 
control levels. By the recovery period, however, cortisol 
levels had begun to decrease and approximated the value at 
the 10-minute hypotensive period. 
'· 
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Figure 3. Comparison of plasma cortisol levels (mean plus 
or minus SEM) before, during and after a 30% decrease in 
mean arterial blood pressure in dogs receiving saline, diaz-
epam, lorazepam or midazolam prior to the hypotension. Sam-
ple periods are: (1) prior to the hypotension (prestress 
control); (2-4) 2, 10 and 20 minutes after stable hypoten-
sion; and (5) 20 minutes after blood pressure returned to 
prestress control levels. The asterisk indicates a signifi-
cant difference (p<.05) between the indicated value and its 
corresponding prestress control value. 
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The effect of benzodiazepines on plasma cortisol lev-
els (Figure 3) is not as striking as the effect of benzo-
diazepines on plasma catecholamine levels. Although there 
was some attenuation of the hypotension-induced surge in 
plasma cortisol levels, significant increases were still 
seen in animals pretreated with both diazepam and midazolam. 
In the diazepam-treated animals, the maximum increase (45%) 
in plasma cortisol occurred at the 20-minute hypotensive 
period, but no other significant increases were seen. The 
midazolam-treated animals showed significant increases in 
plasma cortisol levels at both the 20-minute hypotensive 
period and on recovery. The maximum increase, however, was 
33%, considerably less than the 73% increase seen in the 
control animals. The lorazepam-treated animals differed 
from the other benzodiazepine-treated animals in that no 
significant elevations in plasma cortisol levels were seen 
in these animals, although a relatively large (49%) increase 
was seen on recovery. The lorazepam group also differed 
from the other experimental groups in that the prestress 
control plasma cortisol levels of the lorazepam-treated ani-
mals were somewhat lower than those of the other experimen-
tal groups. No procedural variable was found to account for 
the lower prestress control levels of the lorazepam group. 
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As with the catecholamines, lorazepam' s action on cortisol 
may have been in progress. 
ANOVA 
The analysis of variance showed a significant time 
effect which reflects the elevated plasma cortisol levels 
seen during the hypotensive and recovery periods in the con-
trol, diazepam and midazolam groups. No significant drug 
effect or drug*time interaction was seen. Thus, the differ-
ence between the lorazepam group and the other experimental 
groups with regard to prestress control plasma cortisol lev-
els, was not statistically significant. 
Plasma Renin Activity 
Control Animals 
The response of plasma renin activity, as shown in 
Figure 4, was immediate and dramatic. In fact, at the 
2-minute hypotensive period, plasma renin activity had 
increased 134%. Significant elevations in plasma renin 
activity levels were maintained throughout the hypotensive 
period; however, on recovery plasma renin activity had 
fallen almost to prestress control levels. 
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Figure 'I. Comparison of plasma renin activity (mean plus 
or minus SEM) before, during and after a 30% decrease in 
mean arterial blood pressure in dogs receiving saline, diaz-
epam, lorazepam or midazolann prior to the hypotension. Sam-
ple periods are: (1) prior to the hypotension (prestress 
control); (2-4) 2, 10 and 20 minutes after stable hypoten-
sion; and (5) 20 minutes after blood pressure returned to 
prestress control levels. 1rhe asterisk indicates a signifi-
cant difference (p<.OS) between the indicated value and its 
corresponding prestress control value. 
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Figure 4 shows that in contrast to the ability of ben-
zodiazepines to attenuate hypotension-induced surges in 
plasma epinephrine, norepinephrine and cortisol levels, 
these drugs were relatively ineffective in attenuating the 
hypotension-induced rise in plasma renin activity. All 
three benzodiazepine groups showed a response pattern simi-
lar to that of the control animals, with significant eleva-
tions in plasma renin activity during the hypotensive period 
that were not maintained on recovery. It is especially 
interesting to note that plasma renin activity showed 
greater increases above the prestress control value during 
the hypotensive stress in all benzodiazepine groups than in 
the control group. The maximum increase in the control 
group was 134%. Of the benzodiazepine groups, diazepam 
showed a maximum increase of 298%, lorazepam showed a maxi-
mum increase of 191% and midazolam showed a maximum increase 
of 185%. 
ANOVA 
The analysis of variance of plasma renin activity 
showed a significant time effect. However, no significant 
drug effect or drug*time interactions were found. 
100 
Experiment II 
Hemodynamic Measurements 
Control Animals 
In this experiment, the effects of midazolam adminis-
tered 1-1/2 hours before the hypotensive stress were inves-
tigated. Results from the control group, which were 
reported in Experiment I, are redrawn on the figures relat-
ing to this experiment in order to facilitate comparisons 
between control and midazolam-treated animals. 
Midazolam- Treated Animals 
The hemodynamic profile of animals injected with 
midazolam 1-1/2 hours before nitroprusside-induced hypoten-
sion is shown in Table 5. Blood pressure was maintained at 
approximately 30% of prestress control periods during the 
nitroprusside infusion, and a moderate, but statistically 
insignificant increase above the control value, was seen on 
recovery. Heart rate was well maintained during the hypo-
tensive period, but it was significantly decreased on recov-
ery. Cardiac index fell during the hypotensive period, and 
•. 
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Table 5. Hemodynamic profile of dogs injected with midaz-
olam 1-1/2 hours prior to a nitroprusside-induced 30% 
decrease in mean arterial blood pressure. Abbreviations 
used are: MAP, mean arterial blood pressure; HR, heart 
rate; CI, cardiac index; RAP, right atrial pressure; SVRI, 
systemic vascular resistance index; Wedge, pulmonary capil-
lary wedge pressure; and LVSWI, left ventricular stroke work 
index. Values represent means plus or minus SEM. The 
asterisk indicates a significant difference between the 
indicated value and its corresponding prestress control 
value. 
TABLE 5 
MIDAZOLAM GIVEN 1-1/2 HOURS PRESTRESS: HEMODYNAMICS 
Hr2otension 
20 Min 
Prestress Post-
Control 2 Min 10 Min 20 Min Recoverr 
MAP 85+3 56+2* 58+2* 59+ 2* 9i+3 
(rnrn Hg) 
HR 124+6 122+4 119+4 119+4 112+5* (rnin-1) - -
CI 4.9+0.5 3.9+0.3* 4.0+0.3* 4.1+0.2* 4.6+0.1 (L ·rnin-1·M-2) -
RAP 4.3+0.9 2.9+0.7 3.3+0.7 2.9+0.8 5.3+0.9 
(rnrn Hg) -
SVRI 1383+151 1096+72* 1129+97* 1105+73* 1505+93 (dyne·sec•crn-5·M2) - -
Wedge 10.5+1.9 8.7+2.1* 8.0+2.1* 8.2+2.1* 10.7+1.7 (rnrn Hg) 
~ 
0 
LVSWI 40+4 20+2* 23+1* 24+2* 44+3 N (grn · M · M- 2) - -
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rose to approximately the prestress control level. Contrary 
to the relatively stable systemic vascular resistance index 
seen in the control group, this variable was significantly 
decreased in the hypotensive period in the midazolam group. 
Changes in stroke work index and right atrial pressure 
during the hypotensive and recovery periods in the midazolam 
group paralleled changes in the control group, which were 
shown in Table 1. That is, significant decreases in stroke 
work index were seen during the hypotensive period, and no 
statistical differences in right atrial pressure were 
reported during the hypotensive or recovery periods. 
A comparison of the hemodynamic profile of midazolam 
in the first experiment (midazolam I, Table 4) with the 
hemodynamic profile of midazolam in this experiment (midaz-
olam II, Table 5) showed some interesting differences. 
Heart rate and right atrial pressure were better maintained 
in the midazolam II group, while systemic vascular resis-
tance index and wedge pressure were better maintained in the 
midazolam I group. Other hemodynamic variables such as car-
diac index and stroke work index, however, showed similar 
changes in both midazolam groups. 
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ANOVA 
An analysis of variance of control and midazolam II 
groups showed a significant time effect for all hemodynamic 
variables. A significant drug effect was found for cardiac 
index, systemic vascular resistance index and wedge pres-
sure. The only drug*time effect was seen with respect to 
wedge pressure, and is most likely due to the significant 
decreases seen during the hypotensive and recovery periods 
. 
in the midazolam II group, but not in the control group. 
Plasma Catecholamine Levels 
Midazolam- Treated Animals 
Epinephrine. Figure 5 shows plasma epinephrine lev-
els in the control midazolam II groups. During the hypoten-
sive period, plasma epinephrine levels in the midazolam II 
group remained near the prestress level. At the 20-minute 
hypotensive period; however, a statistically nonsignificant 
55% increase was observed. As in the control group, plasma 
epinephrine levels increased in the midazolam II group to 
reach statistical significance in the recovery period. In 
fact, the 98% increase from prestress control levels in the 
recovery period seen in the midazolam II group even exceeded 
105 
.. 
. ,
Figure 5. Comparison of plasma epinephrine levels (mean 
plus or minus SEM) before, during and after a 30% decrease 
in mean arterial blood pressure in dogs receiving midazolam 
1-1/2 hours prior to the hypotension. Control values from 
experiment I are redrawn on this figure. Sample periods 
are: (1) prior to the hypotension (prestress control); 
(2-4) 2, 10 and 20 minutes after stable hypotension; and (5) 
20 minutes after blood pressure returned to prestress con-
trol levels. The asterisk indicates a significant differ-
ence (p<.05) between the indicated value and its correspond-
ing prestress control value. 
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the 64~~ increase seen in the control group, although the 
absolute values in the midazolam II group were somewhat less 
than those of the control group. 
Plasma epinephrine levels in the midazolam II group 
(Figure 5) changed in a manner similar to that of the 
midazolam I group (Figure 1) during the hypotensive period, 
since neither group showed any significant elevations above 
the prestress control period during this time. However, the 
two midazolam groups differed with respect to plasma 
epinephrine levels at the recovery period. Plasma 
epinephrine levels peaked at this time period in the 
midazolam II group, but they approached prestress control 
levels in the midazolam I group. 
Norepinephrine. Plasma norepinephrine levels during 
the hypotensive and recovery periods are shown in Figure 6 
In contrast to the significant elevations in plasma 
norepinephrine seen during the hypotensive period in the 
control group, plasma norepinephrine levels in the midazolam 
II group remained relatively stable, with no significant 
increase seen during either the hypotensive or recovery 
periods. 
In both midazolam study groups the surge in plasma 
norepinephrine levels following the hypotensive stress was 
attenuated by pretreatment with midazolam given either 4 
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Figure 6. Comparison of plasma norepinephrine levels (mean 
plus or minus SEM) before, during and after a 30% decrease 
in mean arterial blood pressure in dogs receiving midazolam 
1-1/2 hours prior to the hypotension. Control values from 
experiment I are redrawn on this figure. Sample periods 
are: (1) prior to the hypotension (prestress control); 
(2-4) 2, 10 and 20 minutes after stable hypotension; and (5) 
20 minutes after blood pressure returned to prestress 
control levels. The asterisk indicates a significant 
difference (p<.05) between the indicated value and its 
corresponding prestress control value. 
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The only 
difference between the midazolam I (Figure 2) and midazolam 
II (Figure 6) groups was that plasma norepinephrine levels 
were somewhat lower in the midazolam II group, and this 
difference was statistically significant at the prestress 
control and 10-minute hypotensive periods. 
ANOVA 
When the plasma catecholamine levels in the control 
group were compared with those of the midazolam II group 
using the analysis of variance procedure, significant time 
and drug effects were found with respect to plasma epineph-
rine levels, and a significant drug effect was found with 
respect to plasma norepinephrine levels. The significant 
drug effect found for both catecholamines reflects the lower 
values of the midazolam II group. 
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Plasma Cortisol Levels 
Midazolam- Treated Animals 
Plasma cortisol levels increased during the hypoten-
sive and recovery periods in the control dogs and animals 
given midazolam 1-1/2 hours prestress 
2-minute hypotensive period, plasma 
(Figure 7). At the 
cortisol levels had 
increased significantly in the midazolam, but not control 
groups. Plasma cortisol levels in the midazolam II group 
then increased 227% above prestress control levels at the 
10-minute hypotensive period, were maintained at the 
20-minute hypotensive period, but fell on recovery. The 
response of the midazolam II group thus was considerably 
greater than that of the control group, since the maximum 
increase in the control group (73%) was not seen until the 
20-minute hypotensive period. The greater percentage 
increase in the midazolam II group, however, is related to 
the prestress control value which was statistically lower 
than that of the control group. 
A comparison of the midazolam I (Figure 3) and midaz-
olam II (Figure 7) groups showed significant elevations in 
plasma cortisol levels at the 20-minute hypotensive and 
recovery periods in both groups; however, the response 
of these groups differed during the early stages of 
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Figure 7. Comparison of plasma cortisol levels (mean plus 
or minus SEM) before, during and after a 30% decrease in 
mean arterial blood pressure in dogs receiving midazolam 
1-1/2 hours prior to the hypotension. Control values from 
experiment I are redrawn on this figure. Sample periods 
are: (1) prior to the hypotension (prestress control); 
(2-4) 2, 10 and 20 minutes after stable hypotension; and (5) 
20 minutes after blood pressure returned to prestress con-
trol levels. The asterisk indicates a significant differ-
ence (p<.OS) between the indicated value and its correspond-
ing prestress control value. 
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hypotension. That is, at the 2- and 10-minute hypotensive 
periods, the significant elevations in plasma cortisol 
levels seen in the midazolam II group were not seen in the 
midazolam I group. No significant differences, however, 
were found at any time period when plasma cortisol levels in 
the midazolam I group were compared with those of the 
midazolam II group. 
ANOVA 
An analysis of variance of the control and midaz-
olam II plasma cortisol levels showed a significant time 
effect and drug~'<'time interaction. The lack of a significant 
drug effect indicates that there were no statistically sig-
nificant differences between these groups. The significant 
drug*time interaction is somewhat puzzling, since in both 
groups plasma cortisol increased during hypotension and then 
fell somewhat by the recovery period; however, the signifi-
cant effect is most likely related to the lower prestress 
control values in the midazolam group. 
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Experiment Ill 
Hemodynamic Measurements 
Control Animals 
The hemodynamic profile of control animals in response 
to thoracotomies is sho~~ in Table 6. Two minutes after the 
retractor was placed between the ribs, blood pressure rose 
slightly, then fell. By 10 minutes of rib spread blood 
pressure was significantly lower than the prestress control 
level. Heart rate fell slightly and significantly 2 minutes 
after the thoracotomy and, like blood pressure, continued to 
fall throughout the experiment. This downward trend was 
also seen with regard to . cardiac index and stroke work 
index, with these hemodynamic parameters reaching statisti-
cal significance at 5 and 10 minutes, respectively. 
Right atrial pressure, systemic vascular resistance 
index and wedge pressure, the only hemodynamic variables to 
show any upward movement, did not reach statistical signifi-
cance. Systemic vascular resistance index was elevated dur-
ing the surgical stress, but this increase did not reach 
statistical significance. 
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Table 6. Hemodynamic profile of control (saline-treated) 
dogs in response to surgical stress. Timing began after the 
retractor was placed between the 5th and 6th ribs. Abbrevi-
at ions used are: MAP, mean arterial blood pressure; HR, 
heart rate; CI, cardiac index; RAP, right atrial pressure; 
SVRI, systemic vascular resistance index; Wedge, pulmonary 
capillary wedge pressure; and LVSWI, left ventricular stroke 
work index. Values represent means plus or minus SEM. The 
asterisk indicates a significant difference between the 
indicated value and its corresponding prestress control 
value. 
TABLE 6 
HEMODYNAMIC PROFILE OF CONTROL DOGS: SURGICAL STRESS 
Rib SEre ad 
20 Min 
Prestress Post-
Control 2 Min 5 Min 10 Min 20 Min Rib SEread 
MAP 85+ 7 89+5 83+6 79+4* 75+4* 71+4* 
(mm Hg) 
HR 112+5 107+2* 107+2* 106+2* 104+2* 104+3* 
(min -1) -
CI (L ·min -1.M- 2) 
3.7+0.3 3.4+0.3 3.3+0.3* 3.2+0.3* 3.1+0.4* 2.9+0.4* 
RAP 3.8+0.4 3.4+0.7 3.5+0.8 4.5+0.4 4.3+0.3 4.3+0.2 
(mm Hg) 
SVRI 1747+156 2061+193 2023+204 1943+205 2004+292 1962+237 
(dyne·sec·cm-S.M2) 
Wedge 7.7+0.8 8.5+0.4 8.3+0.4 8.5+0.5 8.0+0.4 8.2+0.8 
(mm Hg) 
~ 
~ 
LVSWI 37+6 34+3 31+4 29+3* 28+4* 24+3* "'--
(gm·M·M-2) - - -
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Midazolam- Treated Animals 
The hemodynamic profile of the midazolam-treated ani-
mals, shown in Table 7, is quite similar to that of the con-
trol animals. The midazolam group, like the control group, 
showed significant decreases in mean arterial blood pres-
sure, heart rate, cardiac index and stroke work index; and 
nonsignificant increases in right atrial pressure and sys-
temic vascular resistance index. In fact, the only differ-
ence between these two groups was in wedge pressure which 
increased slightly, but significantly, above the prestress 
control level only in the midazolam group. 
ANOVA 
The analysis of variance showed a significant time 
effect for all hemodynamic variables except systemic vascu-
lar resistance index and right atrial pressure. No signifi-
cant drug effect or drug*time interaction were found. 
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Table 7. Hemodynamic profile of midazolam-treated dogs in 
response to surgical stress. Timing began after the retrac-
tor was placed between the 5th and 6th ribs. Abbreviations 
used are: MAP, mean arterial blood pressure; HR, heart 
rate; CI, cardiac index; RAP, right atrial pressure; SVRI, 
systemic vascular resistance index; Wedge, pulmonary capil-
lary wedge pressure; and LVSWI, left ventricular stroke work 
index. Values represent means plus or minus SEM. The 
asterisk indicates a significant difference between the 
indicated value and its corresponding prestress control 
value. 
TABLE 7 
HEMODYNAMIC PROFILE OF MIDAZOLAM DOGS: SURGICAL STRESS 
Rib SEre ad 
20 Min 
Prestress Post-
Control 2 Min 5 Min 10 Min 20 Min Rib SEread 
MAP 89+5 84+4 79+3* 76+3* 75+3* . 69+5* 
(mm Hg) 
HR 122+4 118+5 118+6 116+5* 115+5* 112+6* 
(min-1) -
CI 3.2+0.3 2.8+0.4 2.6+0.4* 2.8+0.3 2.7+0.4* 2.3+0.4* 
(L·min-l·M-2) 
RAP 4.0+0.5 4.3+0.6 4.2+0.5 3.9+0.6 4.3+0.6 4.3+0.4 
(mm Hg) 
SVRI 2178+221 2368+254 2503+290 2161+198 2189+206 2681+680 
(dyne·sec·cm-5·M2) 
Wedge 7.3+1.2 8.3+1.2* 8.3+1.4* 8. 3+ 1. 3 * 8.5+1.2* 8.0+1.1 
(mm Hg) 
f-' 
LVSWI 30+4 25+3* 22+4* 23+3* 22+4* 18+4* N 0 
(_gm • M · M - 2 ) - -
Plasma Catecholamine Levels 
Control Animals 
Epinephrine. Figure 8 shows the plasma epinephrine 
levels following placement of the retractor and after its 
removal. No statistically significant elevations in plasma 
epinephrine levels were seen in the control animals. This 
is somewhat surprising, considering that 5 minutes after rib 
spread plasma epinephrine levels had increased 119%, and 20 
minutes after removal of the retractor the increase was 
141%. However, on a closer examination of the data, a very 
high degree of variability is revealed. In fact, the coef-
ficient of variation (the ratio of the standard deviation 
divided by the mean and multiplied by 100) was 102% 5 min-
utes after rib spread and 75% 20 minutes after removal of 
the retractor. 
Norepinephrine. Plasma norepinephrine levels, like 
plasma epinephrine levels, did not increase significantly in 
response to surgical stress in the control animals (Figure 
9). However, the changes in plasma norepinephrine levels in 
this group were not as great as those in plasma epinephrine, 
since the maximum increase during rib spread was only 14% 
and the increase seen after removal of the retractor was 
47%. This data was also somewhat variable since the coeffi-
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Figure 8. The effect of pretreatment with midazolam on 
plasma epinephrine levels following surgical stress. Sample 
periods are: (1) prior to skin incision (prestress con-
trol); (2-5) 2, 5, 10 and 20 minutes after placement of the 
retractor; and (6) 20 minutes after removal of the retrac-
tor. 
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Figure 9. The effect of pretreatment with midazolam on 
plasma norepinephrine levels following surgical stress. 
Sample periods are: (1) prior to skin incision (prestress 
control); (2-5) 2, 5, 10 and 20 minutes after placement of 
the retractor; and ( 6) 20 minutes after removal of the 
retractor. 
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cient of variation was over 50% both during rib spread and 
following removal of the retractor. 
Midazolam- Treated Animals 
Epinephrine. As shown in Figure 8, no significant 
elevations in plasma epinephrine levels were seen in 
response to the thoracotomy procedure in the midazolam-
treated animals. However, unlike the control animals, the 
elevations in plasma epinephrine in the midazolam group were 
slight, reaching a maximum increase of 3% 20 minutes after 
removal of the retractor, and even decreasing slightly 5, 10 
and 20 minutes after rib spread. Furthermore, the amount of 
variablility seen in these data was considerably less than 
that seen in the control group, since the maximum coeffi-
cient of variation, which occurred 2 minutes after rib 
spread, was only 38% in the midazolam group. 
Norepinephrine. Figure 9 shows that no significant 
changes in plasma norepinephrine were seen in this experi-
ment. However, it is interesting to note that at all time 
periods except 10 minutes after rib spread, plasma norepi-
nephrine levels were decreased slightly from the prestress 
control value. For the most part, these data did not show 
much variability, although 20 minutes after rib spread and 
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removal of the retractor, the coefficient of variation was 
above 50%. It should be noted that the baseline epinephrine 
and norepinephrine levels in the surgically stressed dogs 
were lower than baseline levels in hypotensively stressed 
dogs (cf., Figures 5 and 6). The larger 15-18 kg dogs used 
in the surgery experiments were found to have lower resting 
catecholamine levels compared with the 12-14 kg dogs used 
earlier in the study. 
ANOVA 
When plasma catecholamine levels from the control and 
midazolam groups were subjected to an analysis of variance, 
only the drug effect for epinephrine was significant. This 
suggests that although plasma epinephrine did not show a 
statistically significant increase over the prestress con-
trol value in the control group, this group did respond dif-
ferently from the midazolam-treated animals. Further analy-
sis revealed that the control and midazolam groups differed 
significantly from each other with regard to plasma epineph-
rine levels 10 and 20 minutes after rib spread. 
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Plasma Cortisol Levels 
Control Animals 
Figure 10 shows that surgical stress resulted in sig-
nificant increases in plasma cortisol levels in control ani-
mals. Plasma cortisol levels were significantly increased 
from 5 minutes after rib spread until the end of the experi-
ment, with a maximum increase of 38% occurring 10 minutes 
after rib spread. 
Midazolam- Treated Animals 
Midazolam was as effective in attenuating the surgery-
induced increase in plasma cortisol levels as it was in 
attenuating the hypotension-induced increase in cortisol. 
Figure 10 shows that no statistically significant rises in 
plasma cortisol levels in the midazolam group occurred while 
the retractor was in place, although the levels did gradu-
ally increase during rib spread. Twenty minutes after the 
retractor was removed, however, cortisol levels increased 
significantly to 37% above the prestress control value. 
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Figure 10. The effect of pretreatment with midazolam on 
plasma cortisol levels following surgical stress. Sample 
periods are: (1) prior to skin incision (prestresss con-
trol); (2-5) 2, 5, 10 and 20 minutes after placement of the 
retractor; and (6) 20 minutes after removal of the retrac-
tor. The asterisk indicates a significant difference 
(p<. 05) between the indicated value and its corresponding 
prestress control value. 
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ANOVA 
A comparison of plasma cortisol levels in the control 
and midazolam groups using the analysis of variance showed 
significant time effect. However, no significant drug 
effect or drug*time interaction was found. 
Plasma Renin Activity 
Control Animals 
The changes in plasma renin activity in control ani-
mals in response to surgical stress are shown in Figure 11. 
In contrast to the large elevation in plasma renin activity 
seen following a hypotensive stress (Figure 4), plasma renin 
activity remained quite stable during the 20 minutes that 
the retractor was in place between the ribs. However, 20 
minutes after the retractor was removed, plasma renin activ-
ity increased 49% above prestress control values. This 
increase, while statistically significant, is quite moderate 
compared with the 134% increase in control animals during 
the hypotensive stress. 
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Midazolam-Treated Animals 
The response of plasma renin activity in animals pre-
treated with midazolam is shown in Figure 11. In these ani-
mals, plasma renin activity showed an upward trend from 5 
minutes after rib spread until the end of the experiment. 
Like the control group, no significant changes in plasma 
renin activity were seen during the 20 minutes that the 
retractor was in place; however, 20 minutes after removal of 
the retractor, plasma renin activity rose significantly. 
Although the plasma renin activity response in control 
and midazolam-treated animals was statistically similar, the 
magnitude of the response of the animals pretreated with 
midazolam was somewhat greater. For example, 20 minutes 
after rib spread, plasma renin activity had increased 39% 
over the prestress control value in the midazolam-treated 
animals and decreased 7% in the control animals. Further-
more, 20 minutes after removal of the retractor, a 93% 
increase over prestress control values was seen in the 
midazolam-treated animals, while only a 49% increase was 
seen in the control animals. Despite the appearance of 
large differences between the control and midazolam groups, 
no statistically significant difference was found between 
these groups at any time period. 
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Figure 11. The effect of pretreatment with midazolam on 
plasma renin activity following surgical stress. Sample 
periods are: (1) prior to skin incision (prestress con-
trol); (2-5) 2, 5, 10 and 20 minutes after placement of the 
retractor; and (6) 20 minutes after removal of the retrac-
tor. The asterisk indicates a significant difference 
(p<. 05) between the indicated value and its corresponding 
prestress control value. 
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ANOVA 
A comparison of plasma renin activity in the control 
and midazolam groups using an analysis of variance showed a 
significant time effect and drug*time interaction and an 
insignificant drug effect. 
Heart Rate and Blood Pressure Prior to Rib Spread 
Control Animals 
Each minute from the time of skin incision until 
placement of the retractor, heart rate and blood pressure 
measurements were taken. Figures 12 and 13 show mean 
arterial blood pressure and heart rate in control animals in 
response to skin incision, blunt dissection of muscle tissue 
and perforation of the pleural cavity that occurred during 
the 5 minutes prior to placement of the retractor. Figure 
12 shows that blood pressure increased above the preincision 
control level following skin incision. This increase in 
blood pressure reached statistical significance 4 minutes 
after skin incision, dropped slightly five minutes after 
skin incision, but maintained statistical significance. 
Heart rate, on the other hand, showed a very slight downward 
trend, only reaching statistical significance 5 minutes 
after skin incision. 
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Figure 12. The effect of midazolam on mean arterial blood 
pressure prior to placement of the retractor between the 5th 
and 6th ribs. Timing began immediately before skin incision 
and continued for five minutes. The asterisk indicates a 
significant difference (p<. 05) between the indicated value 
and its corresponding preincision control value. 
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Figure 13. The effect of midazolam on heart rate prior to 
placement of the retractor between the 5th and 6th ribs. 
Timing began immediately before skin incision and continued 
for five minutes. The asterisk indicates a significant 
difference (p<.05) between the indicated value and its 
corresponding preincision control value. 
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Midazolam- Treated Animals 
The changes in heart rate and mean arterial blood 
pressure in the first 5 minutes following skin incision are 
shown in Figures 12 and 13. Blood pressure in the midazolam 
group showed a significant increase 2 minutes after skin 
incision and then slowly returned to the preincision control 
level. Heart rate, like blood pressure, was somewhat more 
stable in the midazolam group. In fact, the maximum devia-
tion from from the preincision control level was 2 beats/ 
minute, and at no time did heart rate change significantly 
from preincision control levels. 
ANOVA 
An analysis of variance was used to compare the con-
trol and midazolam groups with respect to blood pressure and 
heart rate. The results showed a significant time effect 
and a nonsignificant drug effect for both blood pressure and 
heart rate. Only blood pressure showed a significant 
drug*time interaction, and this reflects the increased blood 
pressure in the control group and decreased blood pressure 
in the midazolam group in the 5 minutes following skin inci-
sion. The significant time effect taken with the insignifi-
cant drug effect suggests that although there were changes 
in the control and midazolam groups in both heart rate and 
141 
blood pressure during ~he 5 minutes following skin incision, 
the groups did not differ significantly from each other with 
regard to these two hemodynamic variables. 
CHAPTER IV 
DISCUSSION 
Highlights of the Results 
Stress Responses in Anesthetized Control Animals 
This study was undertaken to investigate changes in 
plasma catecholamines, cortisol and renin activity and sev-
eral hemodynamic variables following either a hypotensive 
stress or surgical trauma. Further studies then examined 
whether three benzodiazepines could attenuate these stress 
responses. 
Hemodynamic Variables 
Hypotensive Stress. Sodium nitroprusside, Nipride, 
was used to produce the hypotensive stress in Experiments I 
and II. The hypotensive effect of this drug is immediate 
and ends within minutes after termination of the infusion. 
Nitroprusside is rapidly metabolized to cyanide and subse-
quently converted to thiocyanate (Roche Laboratories, 1982). 
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Nitroprusside is a potent vasodilator that acts 
directly on the smooth muscle of both resistance and capaci-
tance vessels (Nickerson and Ruedy, 1975). Nitroprusside 
does not appear to have any direct cardiac effects (Chiba et 
al., 1982). Most effects on measurements of cardiac per-
formance appear to be secondary to the reduction in periph-
eral resistance and venous tone, which alter afterload and 
preload, respectively (Palmer and Lasseter, 1975). Also, 
nitroprusside has not been shown to have any effects on the 
autonomic or central nervous systems, and there is no evi-
dence that its effects are mediated by these systems (Palmer 
and Lasseter, 1975). 
Although blood pressure is decreased in both dogs and 
humans following nitroprusside administration, the overall 
pattern of cardiovascular responses is inconsistent. Adams 
(1974) and Rowe and Henderson (1975) reported that heart 
rate was significantly increased in anesthetized dogs, but 
decreases and only slight increases have also been reported 
(Chiba et al., 1982). Cardiac output was found to be 
increased (Rowe and Henderson, 1975) and unchanged (Adams, 
1974). Stroke volume was shown to be decreased (Adams, 
1974) or increased (Rowe and Henderson, 1975). Decreases in 
systemic vascular resistance index, wedge pressure and right 
atrial pressure have been reported (Adams, 1974; Rowe and 
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Henderson, 1975). In unanesthetized normotensive and hyper-
tensive human patients, nitroprusside produced a marked low-
ering of arterial blood pressure, slight increase in heart 
rate, mild decrease in cardiac output, and moderate diminu-
tion in calculated total peripheral vascular resistance 
(Roche Laboratories, 1982). 
In the present study, the hemodynamic profile of the 
dogs remained relatively stable during the nitroprusside 
infusion. Cardiac index and stroke work index, the only 
variables other than arterial blood pressure to change sig-
nificantly during the infusion, were significantly decreased 
both during the infusion and on recovery. The decreases 
found in cardiac index and stroke work index are probably 
due to the statistically significant decreases in systemic 
vascular resistance index reflecting arteriolar vasodila-
tion. Statistically nonsignificant decreases in heart rate, 
right atrial pressure and wedge pressure were also found. 
The lack of many significant cardiovascular responses 
in the control animals probably was related not only to the 
effects of nitroprusside, but also to the enflurane-nitrous 
oxide-oxygen anesthesia used in this study. Enflurane often 
causes decreases in systemic vascular resistance index and 
cardiac output, but cardiac rhythm generally remains stable 
(Hall and Boulton, 1979). The addition of nitrous oxide to 
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enflurane anesthesia is reported not to increase the cardio-
vascular depressant effects of enflurane, but rather to 
reduce the magnitude of the decrease in heart rate and blood 
pressure (Smith et al., 1978). 
Surgical Stress. The animals in Experiment III were 
stressed by skin incision and thoracotomy. Numerous studies 
have documented hemodynamics and catecholamine responses to 
both abdominal and thoracic surgery. Hoar et al. (1980b) 
and Kim et al. (1981) reported hemodynamic reponses to ster-
notomy in patients undergoing myocardial revascularization. 
Sternotomy and cardiopulmonary bypass cause the greatest 
overall sympathetic stimulation in surgical patients. 
Although anesthesia was maintained with halothane-nitrous 
oxide-oxygen by Hoar et al. and with enflurane-nitrous 
oxide-oxygen by Kim et al., both of these groups found 
increases in heart rate, mean arterial blood pressure, and 
systemic vascular resistance index following sternotomy. 
In the present study, skin incision and rib spread 
caused statistically significant decreases in mean arterial 
blood pressure, heart rate, cardiac index and stroke work 
index were found. Systemic vascular resistance index 
increased, but this was not statistically significant. The 
results of this study and those of Hoar et al. (1980b) and 
Kim et al. (1981) demonstrate that hemodynamics and sympa-
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thetic responses relate to the intesity of the stresses. 
While ribs were spread in this study, they were not broken, 
and thus would not have provided as strong a stress as the 
sternotomy in the Hoar et al. and Kim et al. studies. 
Also, Hoar et al. (1980b) administered morphine sulfate, 
scopolamine, thiopental and curare to their patients prior 
to the sternotomy; and Kim et al. (1981) administered mor-
phine sulfate, scopolamine, thiopental, succinylcholine and 
pancuronium to their patients. However, the only drug other 
than the anesthetic mixture administered in the present 
study was thiopental on induction of anesthesia. 
Catechol ami nes 
The nitroprusside-induced hypotension resulted in sta-
tistically significant increases in plasma epinephrine and 
norepinephrine. 
Steriods have been reported to inhibit the extraneu-
ronal uptake of catecholamines in the rat heart (Iverson and 
Salt, 1970) and in smooth muscle (Nicol and Rae, 1972). An 
inhibition of the normally rapid inactivation of catechola-
mines by tissue uptake would be expected to produce higher 
concentrations of catecholamines in the vicinity of adrener-
gic receptors. This, in turn, could produce exaggerated and 
prolonged pharmacological responses. 
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Nicol and Rae (1972) reported 50% inhibition of cate-
cholamine uptake 2 in peripheral arteries with plasma corti-
sol levels of 69.2 ng/ml; much less than required to inhibit 
uptake 2 in heart (Iverson and Salt, 1970). In the present 
experiments, cortisol levels in control animals increased 
during the stress. Peak levels, above 70 ng/ml, were seen 
10 and 20 minutes following the surgical and hypotensive 
stresses, respectively. In these same animals, catechola-
mine levels rapidly increased, within two minutes, in 
response to stress and tended to remain elevated. Even 
though some degree of uptake 2 inhibition may have been 
present, the lack of an association between peak cortisol 
and catecholamine levels, 2 minutes vs 10 minutes, suggests 
that cortisol was not a major determinant of the early rise 
in catecholamine levels and pharmacological actions in vivo 
following hypotensive or surgical stresses. 
The stress response to the thoracotomy procedure, 
while showing the same trend as the hypotensive stress, was 
considerably milder. 
Based on the results of previous clinical studies, 
(Anton, 1964; Halter et al.,l977; Balasaraswathi et al., 
1978 and 1980; Madsen et al., 1978; Tan et al., 1978; Hoar 
et al., 1980a and 1980b; Kim et al., 1981) it was assumed 
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that surgical stress &uch as thoracotomy used in this study 
would be a potent stimulant to plasma catecholamine levels. 
Although a large increase in both epinephrine and norepi-
nephrine were seen following the thoracotomy procedure, 
these increases were not statistically significant. 
Because most of the previous studies showing an 
increase in catecholamines in response to thoracotomy used 
patients with myocardial disorders, it might seem that there 
is a marked difference in the physiologcial response to sur-
gical stress in patients with and without cardiovascular 
disorders. However, Barta et al. (1976) measured the 
release of dopamine-beta-hydroxylase, an enzyme involved in 
norepinephrine synthesis, into coronary blood after thoraco-
tomy and during cardiopulmonary bypass in patients undergo-
ing correction of a mitral valve defect. Their results sug-
gested that while thoracotomy alone was not a stimulus that 
would lead to increased sympathetic activity in the heart, 
the cardiopulmonary bypass surgery led to considerable sym-
pathetic activity in the heart. These results may however 
reflect a difference between cardiac and generalized sympa-
thetic activation. In studies of patients with cardiovascu-
lar disorders, some researchers show increased sympathetic 
activity in response to certain surgical stresses while oth-
ers do not. Consequently, the inability of the control cat-
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echolamine data to reach statistical significance following 
rib spread was most likely due to the large amount of vari-
ability in the data, and reflects the variability of the 
plasma catecholamine response to the thoracotomy procedure. 
The possibility also exists that the sympathetic response of 
individuals to surgical stress does not conform to a para-
metric statistical analysis. 
Cortisol 
Cortisol was significantly elevated in response to 
both the hypotensive and surgical stresses. Although the 
maximum amount of elevation during the hypotensive stress 
(73%) was greater than that during the surgical stress 
(38%), elevations in cortisol generally were of similar mag-
nitude during both stresses. Since the magnitude of the 
catecholamine and renin response to the hypotensive stress 
was considerably greater than that of the thoracotomy 
stress, it would seem that while catecholamines and renin 
activity are quite sensitive to alterations in blood pres-
sure, cortisol secretion is elicited by a wider variety of 
stressful situations. 
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Plasma Renin Activity 
The effect of surgical stress on plasma renin activity 
was markedly less than that of the hypotensive stress. 
Plasma renin activity, which increased 134% over the pre-
stress control level during the hypotensive stress, showed 
nonsignificant increases following rib spread and only 
reached significance with a 49% increase 20 minutes after 
removal of the retractor. Unlike the catecholamine data, 
the small rise in plasma renin activity following thoraco-
tomy cannot be attributed to excessivie variability in these 
data; however, the moderate increase in plasma renin activ-
ity may be related to the smaller degree of elevated cate-
cholamines, since sympathetic nerve activity is one stimulus 
to renin release. 
A second reason that plasma renin activity was not as 
elevated following the surgical stress is that during the 
thoracotomy procedure, blood pressure, which was lowered 30% 
during the hypotensive stress, only decreased a maximum of 
16% following surgical trauma; consequently, afferent renal 
artery blood pressure, an important factor in renin release, 
probably was not sufficiently lowered to initiate a large 
release of renin. 
Finally, alterations in fluid balance, another impor-
tant factor in renin release, were probably not a factor in 
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either stress-producing procedure, since fluid balance was 
maintained by careful monitoring of fluid intake and output. 
Stress Reduction by Benzodiazepines 
Hemodynamic Variables 
There were no outstanding differences between the ben-
zodiazepine and control groups or between any of the three 
benzodiazepine groups during the hypotensive stress. In 
fact, the only noteworthy hemodynamic change was a statisti-
cally significant decrease in heart rate and right atrial 
pressure seen following midazolam pretreatment; however, the 
magnitude of the decrease in both of these variables was not 
great. During the thoracotomy stress, the hemodynamic pro-
file of animals pretreated with midazolam approximated that 
of control animals. The results suggest that with respect 
to hemodynamic variables, control animals and benzodiaze-
pine-treated animals respond similarly to hypotensive and 
surgical stresses. 
Catecholamines, Cortisol and 
Renin Activity 
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The results indicate that diazepam, midazolam and lor-
azepam are all capable of blunting the elevated plasma epi-
nephrine, norepinephrine and cortisol levels seen in 
response to a hypotensive stress. Although plasma catechol-
amines and cortisol levels appeared to be decreased to a 
greater extent following diazepam pretreatment, the degree 
of suppression of midazolam and lorazepam was only slightly 
less than that of diazepam. On the other hand, none of the 
benzodiazepines were effective in suppressing stress-induced 
elevations in plasma renin activity. Although there are 
definite pharmacodynamic and chemical differences between 
diazepam, lorazepam and midazolam, the results of this study 
do not recommend one over the other for attenuation of 
stress responses of short duration. 
Time Course of 
Midazolam's Actions during 
Hypotensive Stress 
Because the ability of diazepam and lorazepam to sup-
press the hypotension-induced stress responses was similar 
to that of midazolam, the new water-soluble benzodiazepine, 
midazolam was chosen for further investigation. When midaz-
olam was administered 1-1/2 hours prior to the hypotensive 
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stress, it was able to blunt both the norepinephrine and 
epinephrine stimulatory response to a hypotensive stress. 
However, cortisol levels remained elevated throughout the 
hypotensive and recovery periods. 
In comparing these results with those from the experi-
ment in which midazolam was given 4 minutes prior to the 
stress, it appears that midazo1am effected a stronger sup-
pression when given just before the stress. When midazolam 
was given 4 minutes prestress, the largest increase in epi-
nephrine was statistically insignificant (40%) and norepi-
nephrine decreased 14%. On the other hand, when midazolam 
was given 1-1/2 hours prestress, a 98% rise in epinephrine, 
which was statistically significant, was seen during the 
recovery period, and norepinephrine showed a nonsignificant 
46~~ increase during the hypotensive period. Also, plasma 
cortisol levels, which were attenuated during the first 10 
minutes of the hypotensive period when midazolam was given 
just prior to the stress, were not attenuated when midazolam 
was given 1-1/2 hours prestress. The entire time course of 
midazolam' s actions on plasma catecholamines and cortisol 
were not determined in this study. The results suggest that 
midazolam is effective in suppressing the stress-induced 
surges in catecholamines for a longer duration of time than 
it is effective in suppressing stress-induced elevations in 
cortisol. 
Effects of Midazolam OfJ 
Surgical Stress Responses 
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In the thoracotomy experiment, as in the hypotensive 
experiment, midazolam was effective in reducing the stress-
induced elevations in cortisol levels, but did not affect 
plasma renin activity. The catecholamine data in control 
animals in the thoracotomy experiment were not as markedly 
elevated as they were in the control animals in the hypoten-
sive experiment. Also, there was a large amount of vari-
ability in the catecholamine data from control dogs that was 
not seen in midazolam-treated dogs. Thus, it is possible 
that midazolam was effective in counteracting surgery-in-
duced elevations in catecholamines in those instances where 
the subject was predisposed to stress-induced elevations of 
catecholamines. 
Summary 
One might speculate on the potential clinical benefits 
of benzodiazepines on stress-induced elevations in plasma 
catecholamines, cortisol and renin activity in patients. 
The data from this animal study indicate that when a situ-
ation, such as drug-induced hypotension or surgical trauma, 
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is expected to result in levated plasma catecholamines, cor-
tisol and renin activity then benzodiazepines could be of 
value in obtunding the catecholamine and cortisol, but not 
renin activity, stress response. Moreover, when an eleva-
tion in catecholamines cannot be definitely predicted, in a 
situation analogous to the thoracotomy procedure, benzo-
diazepines might also be effective in inhibiting potential 
rises in plasma catecholamines. It is anticipated that 
controlled clinical studies will establish the similarities 
of patient responses to benzodiazepines with the reponses 
obtained in this study. 
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Anesthetic Actions of Benzodiazepines 
Since all of the benzodiazepines used in this study 
are capable of inducing anesthesia, it might seem reasonable 
to assume that the stress-inducing actions of benzodiaze-
pines merely reflected an increased depth of anesthesia. In 
other words, the attenuation in the adrenergic and cortisol 
response to surgical or hypotensive stress by benzodiazepine 
premedication may have resulted from a generalized depres-
sion caused by the addition of a second anesthetic agent 
(benzodiazepines) to the ongoing enflurane-nitrous oxide-ox-
ygen anesthesia. 
However, results from a pilot study done in this labo-
ratory demonstrated that using nitrous oxide to increase the 
depth of anesthesia to the level to which the benzodiaze-
pines might have increased it did not blunt the hypotension-
induced rise in epinephrine and norepineprhine. This study 
used the Melvin et al. (1980) criteria to approximate the 
increased depth of anesthesia that the dose of midazolam 
used in our study (0.2 mg/kg) would yield. The Melvin group 
found that midazolam reduced the halothane MAC in a dose-de-
pendent manner, and extrapolating from their results to the 
dose of midazolam used in our study, midazolam would appear 
to decrease the volume percent of enflurane to achieve 
157 
enflurane MAC by 10%. In the pilot study, the anesthetic 
delivered was increased from the 1.3 MAC used in the present 
study to 1. 5 MAC (a 15.4% increase). This was a slightly 
greater increase than that predicted by the results of the 
Melvin et al. study. The amount of nitrous oxide that 
would cause this multiple of MAC was calculated to be 40% in 
60% oxygen. 
One subject in the pilot study showed a 102% increase 
in norepinephrine and another subject showed a 105% increase 
in norepinephrine. Thus, even though the benzodiazepines 
may have slightly increased the depth of anesthesia, the 
response of plasma catecholamines to stress appears to be 
active at the level of anesthesia used in the pilot study. 
Consequently, the attenuation of stress-induced elevations 
in plasma epinephrine, norepinephrine, and cortisol found in 
benzodiazepine-treated animals in the present study does not 
appear to be due to a generalized anesthesia-induced depres-
sion. 
In addition, the intravenous administration of 0. 2 
mg/kg midazolam to awake dogs in the 1-1/2 hour pretreatment 
study caused only minimal observable changes in the dog's 
behavior. The dogs remained awake and responsive, although 
they appeared less anxious. In a purely subjective sense 
the dogs could have been characterized as sedated. 
Pharmacological Basis of the Results 
Overview of Benzodiazepine Receptors 
Peripheral versus Central Site 
of Action 
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The benzodiazepines could have attenuated the stress 
responses in the study by acting at a site either within or 
outside of the central nervous system. Benzodiazepines have 
been reported to bind specifically to both central and 
peripheral sites (Braestrup & Squires, 1977; Mohler and 
Okada, 1977; Davies and Huston, 1981). However, benzodiaze-
pine binding to kidney, liver and lung tissue is pharmacolo-
gically distinct from binding to brain tissue, with the 
peripheral binding sites showing significantly lower affini-
ties for benzodiazepines than central sites (Braestrup and 
Squires, 1977). Furthermore, the displacement of 
3 H-diazepam from central binding sites by clinically active 
benzodiazepines correlated well with an in vitro anti-anxi-
ety test and with recommended clinical doses (Braestrup et 
al., 1977). No such correlation, however, was found for 
peripheral sites (Braestrup and Squires, 1977). The results 
of these pharmacological studies thus suggest that periph-
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eral binding sites do not mediate the clinical effects of 
benzodiazepines. 
Electrophysiological studies also do not support a 
peripheral site of action for the benzodiazepines. Diazepam 
could only inhibit nictitating membrane contraction or pupil 
dilation following preganglionic cervical nerve stimulation 
at doses well above therapeutic concentrations (Chai and 
Wang, 1966; Sigg et al., 1971). Furthermore, no dose of 
diazepam affected postganglionic stimulation in the Chai and 
Wang study. However, diazepam was effecive in inhibiting 
centrally evoked sympathetic responses in both of these 
studies. Consequently, results from both pharmacological 
and electrophysiological studies would suggest that the ben-
zodiazepines used in this study most likely would have acted 
at sites within rather than outside of the central nervous 
system to attenuate the stress-induced stimulatory responses 
seen in this study. 
Benzodiazepine Receptors in 
the Central Nervous System 
Benzodiazepine receptors are well distributed through-
out the central nervous system. Studies of both human and 
rat brains have indicated that the frontal cortex, occipital 
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cortex, limbic forebrain and hippocampus contain the highest 
density of benzodiazepine binding sites; hypothalamus, cere-
bellum and corpus striatum show a moderately high density of 
binding sites; and the pons and medulla contain the lowest 
density of binding sites (Braestrup and Squires, 1977; 
Braestrup et al., 1977). Because benzodiazepine binding to 
these central sites is saturable and specific, occurs with 
high affinity and has a good correlation between the in vivo 
potency and binding strength, the central benzodiazepine 
binding sites are considered to be pharmacologically rele-
vant receptors (Braestrup and Squires, 1978; Speth et al., 
1980). 
Although the early studies of Squires and Braestrup 
(1977) indicated that only one class of benzodiazepine 
receptors exists in the central nervous system, more recent 
studies have suggested that there are actually two classes 
of benzodiazepine receptors, which can be differentiated by 
the binding of a new class of agents, the triazolopyrida-
zines (Squires et al., 1979; Lippa et al., 1979) In fact, 
Klepner et al. (1979) have suggested that both benzodiaze-
pines and triazolopyridazines bind to Type I benzodiazepine 
receptors and mediate anxyolytic actions. In contrast Type 
II benzodiazepine receptors appear only to bind to benzo-
diazepines with high affinity, are considered to be coupled 
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to GABA (gamma-aminobutyric acid) receptors and mediate 
nonanxyolytic pharmacological effects. 
Thus, after considering the current state of knowledge 
of benzodiazepines, it can be assumed that the benzodiaze-
pines in the present study attenuated stress responses by 
acting at central Type II benzodiazepines receptors. 
Ben zodiazepi ne- CABA- Chloride 
lonophore Receptor Complex 
A large body of evidence suggests that many of the 
pharmacological effects of benzodiazepines can be attributed 
to their actions on GABA systems in the brain. In 1975 
Haefely et al. proposed that GABA might be involved in the 
central actions of benzodiazepines since benzodiazepines' 
anticonvulsant, muscle relaxant, ataxic and sedative 
effects, but not their anxyolytic effects, resemble accepted 
or presumed functions of GABA. Haefely et al. also showed 
that benzodiazepines could counteract convulsions associated 
with a partial inhibition of brain GABAergic transmission, 
enhance GABA-mediated presynaptic inhibition in the spinal 
cord and cuneate nucleus, and facilitate GABAergic postsy-
naptic inhibition in the substantia nigra. 
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Costa et al. and Fuxe et al. also suggested in 1975 
that GABA was involved in the action of benzodiazepines. 
Costa et al. showed that benzodiazepines could reduce the 
increase in cerebellar cyclic GMP content generated by a 
decrease in GABAergic transmission, and Fuxe et al. showed 
that although benzodiazepines could reduce central dopamine 
and norepinephrine turnover, these effects could be 
explained by an increase in GABA-receptor activity. 
Further evidence for a benzodiazepine-GABA interaction 
comes from Enna (1979) who found a very high correlation 
between the regional distribution of 3 H-benzodiazepine bind-
ing sites and 3 H-GABA binding sites. Also, Tallman et al. 
(1978) have shown that while GABA and the GABA agonist mus-
cimol could increase the affinity of benzodiazepines for 
their binding sites without changing the number of binding 
sites, this effect could be blocked by bicuculline, a com-
petitive GABA antagonist. Thus, at the present time it is 
generally agreed that GABA is intimately involved in many 
actions of the benzodiazepines. 
In addition to the postulated benzodiazepine-GABA 
interaction, benzodiazepines appear to interact with a chlo-
ride ionophore. Martin and Candy (1980) have shown that 
increasing chloride ion concentrations facilitate benzo-
diazepine binding. It has also been shown that GABA-medi-
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ated depolarization is due to increased chloride conductance 
(Nishi et al., 1974). Thus, a close linkage between the 
benzodiazepine receptor, GABA receptor and chloride iono-
phore has been proposed by Costa and Guidotti (1979), Gal-
lager et al., (1980), Martin and Candy (1980) and Paul et 
al. (1981). 
According to this supramolecu1ar theory of benzodiaze-
pine action, GABA occupation of the postsynaptic receptor 
opens the chloride ionophore allowing chloride ions to pass 
through the membrane according to the concentration gradi-
ent. A chloride ion flux into a cell results in hyperpolar-
ization of the cell membrane, a reduction in the response of 
the cell to incoming excitatory stimuli and postsynaptic 
inhibition. On the other hand, a chloride flux from a nerve 
cell terminal results in depolarization of the nerve termi-
nal, a reduction in the amount of neurotransmitter released 
from the cell and presynaptic inhibition. Benzodiazepines 
are thought to act by enhancing this GABA-induced increase 
in chloride conductance. 
In summary, benzodiazepine receptors appear to be part 
of a supramolecular complex consisting of a benzodiazepine 
receptor, GABA receptor and chloride ionophore. Benzodiaze-
pines appear to mediate their effects by enhancing the 
GABAergic increase in chloride conductance. Although the 
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present study was not designed to further investigate the 
supramolecular complex as the mechanism of benzodiazepine 
action, this theory does allow for a better understanding 
of some of the effects of benzodiazepines seen in this 
study. 
Central Benzodiazepine Receptors and Hypotensive Stress 
Central Benzodiazepine 
Actions and Catecho/amines 
Plasma epinephrine and norepinephrine levels were sig-
nificantly elevated following the hypotensive stress, and 
each of the benzodiazepines used in this study effectively 
attenuated the response of the catecholamines to this 
stress. Assuming that the benzodiazepines do indeed act at 
central rather than peripheral sites, then the effects of 
benzodiazepines on plasma catecholamine levels would be 
reflective of a primary action within the central nervous 
system. The benzodiazepines do not appear to have acted at 
the level of the medulla, because these drugs have been 
shown to be either ineffective inhibitors of pressor or 
depressor responses obtained by stimulation of the medulla 
(Antonaccio and Halley, 1975) or only slightly effective 
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inhibitors of these responses (Chai and Wang, 1966). 
Although this is not surprising considering that the medulla 
is only sparsely populated with benzodiazepine receptors 
(Braestrup et al., 1977; Braestrup and squires, 1977; Mohler 
and Okada, 1977), this is an instance of dissociation 
between GABA and benzodiazepine actions. 
More likely sites of benzodiazepine actions would 
include the hypothalamus and other supramedullary structures 
involved in sympathetically mediated functions. An early 
study by Chai and Wang (1966) showed that the hypothalamus 
was considerably more susceptible than the medulla or 
peripheral sites to diazepam's centrally mediated depressant 
effects. Sigg et al. (1971) subsequently showed that diaze-
pam could inhibit a hypothalamically evoked vasopressor 
response. Further evidence supporting a hypothalamic site 
of the sympathetic actions of benzodiazepines comes from 
binding studies. Several investigators have reported a high 
concentration of binding sites in the hypothalamus 
(Braestrup et al., 1977; Braestrup and Squires, 1977; Mohler 
and Okada, 1977). Furthermore, GABA has been shown to be 
involved in sympathetically mediated cardiovascular 
responses and a forebrain site of action has been implicated 
by DiMicco et al. (1977). In fact, Anotnaccio and Halley 
(1975) have shown that benzodiazepines can mediate autonomic 
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activity at such caudal areas as the rostral periaqueductal 
grey and dorsal tegmentum. Antonaccio (1979) later sug-
gested that these more caudal areas may help form tracts 
that synapse with bulbospinal tracts and then connect with 
preganglionic neurons to mediate sympathetic activity. 
Consquently, benzodiazepines do not appear to act exclu-
sively at the hypothalamus, but may act throughout well-de-
fined supramedullary centers. 
The means by which benzodiazepines regulate peripheral 
sympathetic activity can be considered by examining the 
effects of benzodiazepines on central catecholamines. Cor-
rodi et al. (1971) have suggested that the inhibitory effect 
of benzodiazepines on stress-induced increases in norepi-
nephrine turnover may be due to a reduction in nervous 
impulse flow, and their suggestion is supported by studies 
by Taylor and Laverty (1973) and Lidbrink and Farnebo 
(1973). Taylor and Laverty showed that benzodiazepines had 
no significant effect on endogenous catecholamine levels 
throughout the rat brain, on the uptake of catecholamines 
into catecholaminergic neurons or on catecholamine metabo-
lism. In the Lidbrink and Farnebo study, the authors used 
cerebral cortex slices from rat brains to confirm that ben-
zodiazepines are ineffective inhibitors of norepinephrine 
uptake and to further show that benzodiazepines do not 
r 
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affect catecholamine release. Thus, the effects of benzo-
diazepines on the stress-induced increases in plasma norepi-
nephrine and epinephrine seen in the present study most 
probably were due to a decrease in neuronal activity and 
involved supramedullary sites of the central nervous system. 
On the other hand, because of the wide distribution of 
both GABA and benzodiazepine receptors within the central 
nervous system, and because other central nervous system 
areas such as the cortex and limbic system may affect sympa-
thetically mediated functions (Antonaccio, 1977), benzo-
diazepines may act at areas other than the hypothalamus. 
Thus, benzodiazepines appear to attenuate cardiovascular 
responses at a site caudal to the medulla, possibly involv-
ing the hypothalamus, and the sympathetic effects of benzo-
diazepines may be related to GABAergic actions. 
Benzodiazepines and Stress-
Induced Elevations in Cortisol 
Plasma cortisol levels were significantly elevated in 
response to both the hypotensive and surgical stresses, and 
this response was attenuated by the benzodiazepines. 
Although the specific means by which the benzodiazepines 
produced this effect cannot be determined from this study, 
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possible explanations can be entertained by considering 
reported effects of benzodiazepines and GABA on the cortisol 
secretory process. 
Plasma cortisol levels are determined by a complex 
interplay between the hypothalamus, anterior pituitary and 
adrenal cortex (Guyton, 1976). Cortisol is secreted from 
the adrenal cortex, and the rate of secretion is controlled 
almost entirely by adrenocorticotropic hormone (ACTH). ACTH 
secretion is in turn thought to be primarily controlled by a 
hypothalamic releasing factor, corticotropin releasing fac-
tor (CRF). In addition, there is also a direct inhibitory 
feedback of cortisol on the hypothalamus and anterior pitui-
tary. Thus, continuing with the previously discussed 
assumption that benzodiazepines have a central rather than 
peripheral site of action, the attenuation of the plasma 
cortisol stress response would most likely have occurred at 
the level of either the hypothalamus or anterior pituitary. 
Because the effects of benzodiazepines on CRF and ACTH 
secretion are not well defined, it might be useful to exam-
ine the role of GABA, the neurotransmitter thought to medi-
ate the actions of the benzodiazepines, in the hypothalamus 
and anterior pituitary. Makara and Stark (1974) showed that 
while GABA infused into the third ventricle of rats could 
block a surgery-induced increase in plasma corticosterone 
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levels, picrotoxin, a GABA antagonist, increased plasma cor-
ticosterone levels. Futhermore, this effect held even when 
the hypothalamus was deafferentated, leading these authors 
to suggest that GABA of hypothalamic origin might be 
involved in regulating ACTH secretion. Also, GABA has been 
located in both the anterior pituitary and the hypothalamus 
(Racagni et al., 1981). Moreover, Tappaz et al. (1981) have 
presented evidence that a hypothalamic GABAergic pathway may 
run from the arcuate nucleus to the median eminence and they 
suggest that GABA may act directly on the anterior pitui-
tary. Indications that GABA may act directly on the ante-
rior pituitary come from the identification of GABA binding 
sites in the anterior pituitary of both rat and human brains 
(Grandison, 1981) and from studies that have shown that GABA 
can act on the anterior pituitary to prevent the release of 
prolactin, another anterior pituitary hormone (Cocchi et 
al., 1981; Grandison, 1981; McCann et al., 1981). Further-
more, benzodiazepines have been shown to act at the level of 
the anterior pituitary to potentiate the GABA-induced 
decrease in prolactin (Grandison, 1981). 
In summary, it is most likely that the benzodiazepines 
decreased the cortisol stress response in this study by act-
ing at the level of the hypothalamus and pituitary. 
Although there is evidence suggesting that both GABA and 
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benzodiazepines can act directly on the anterior pituitary, 
benzodiazepine receptors have not yet been located in con-
junction with the proposed anterior pituitary GABA recep-
tors. Furthermore, although evidence showing that GABA, and 
even benzodiazepines, can act directly on the anterior 
pituitary, benzodiazepine receptors have not yet been 
located in conjunction with the proposed anterior pituitary 
GABA receptors. Also, evidence showing that GABA, and even 
benzodiazepines, can act at the anterior pituitary to pre-
vent prolactin release does not prove that GABA and benzo-
diazepines act at the anterior pituitary to inhibit ACTH 
release. Alternatively, the benzodiazepines and GABA could 
act at the level of the hypothalamus and inhibit CRF or some 
similar inhibitory substance. Consequently, although it 
seems likely that the benzodiazepines in the present study 
acted along the hypothalamic-pituitary axis, the exact site 
of action cannot be determined. 
Benzodiazepines and 
Elevations in Plasma Renin 
Activity 
Plasma renin activity was significantly elevated in 
response to the hypotensive stress. However, contrary to 
the attenuation of stress-induced elevations in plasma cate-
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cholamines and cortisol levels by benzodiazepines, these 
drugs were unable to affect the stress-induced rise in 
plasma renin activity. Renin is released from the juxta-
glomerular apparatus of the kidney in response to increased 
sympathetic nerve activity, reduced glomerular filtration 
rate or vasoconstriction of the renal arteries (Sweet, 
1977). Considering that these stimuli are reflective of 
peripheral events and benzodiazepines act primarily at cen-
tral sites, it is not surprising that benzodiazepine pre-
treatment did not attenuate the stress-induced elevation in 
plasma renin activity. Also, although benzodiazepine bind-
ing sites have been found in the kidney, these binding sites 
are pharmacologically distinct from the central binding 
sites (Braestrup and Squires, 1977). Thus, it can be 
assumed that the inability of benzodiazepines to block the 
rise in plasma renin activity seen in response to a hypoten-
sive stress is due to the fact that the benzodiazepines act 
centrally rather than peripherally. 
Summary 
The ability of benzodiazepines to attenuate stress-in-
duced elevations in plasma epinephrine, norepinephrine and 
r 
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cortisol, but not renin activity, is of pharmacological as 
well as clinical interest. Although the present study was 
not designed to investigate the mechanism and site of the 
stress-reducing effects of the benzodiazepines, current lit-
erature suggests that the benzodiazepines act at central 
Type II benzodiazepine receptors, often in conjunction with 
GABA. The inhibitory effects of the benzodiazepines on 
stress-induced elevations of catecholamines and cortisol 
appear to have been mediated at a supramedullary site, pos-
sibly at the level of the hypothalamus or pituitary. On the 
other hand, the benzodiazepines were ineffective in attenu-
ating stress-induced elevations in plasma renin activity, 
and this is considered to be related to the central rather 
than peripheral site of benzodiazepine actions. Further 
studies, of course, are needed to correlate the clinical 
effects of benzodiazepines with their concomitant pharmaco-
logical actions. 
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Significance of this Research to Health Care 
A variety of stressful situations can lead to elevated 
plasma catecholamines, cortisol and renin activity, which 
may at times be undesirable. For example, in cardiac 
patients with ischemic heart disease the physician may wish 
to avoid some of the potential effects of high plasma cate-
cholamine and renin activity levels -- increased afterload 
and ventricular wall tension -- which can lead to increased 
oxygen demand. Moreover, it may be beneficial to avoid ele-
vated plasma cortisol levels in some patients with hypera-
drenocortical function or with labile diabetes. 
In this study, three benzodiazepines attenuated 
stress-induced elevations in plasma epinephrine, norepineph-
rine, and cortisol levels . in anesthetized dogs. Further 
studies are needed to determine whether similiar actions 
occur in human patients. 
BIBLIOGRAPHY 
Adams, A.P., Clarke, T.N.S., Edmonds-Seal, J., Foex, P., 
Prys-Roberts, C., And Roberts, J.G. The Effects of 
Sodium Nitroprusside on Myocardial Contractility and 
Haemodynamics. Br. J. Anaesth., 116: 807-817, 1974. 
Abukhres, M.M., Ertel, R. J., Dixit, B. N. and Vollmer, R. 
R. Role of the Renin-Angiotensin System in the Blood 
Pressure Rebound to Sodium Nitroprusside in the 
Conscious Rat. Eur. J. Pharmacol., 58: 247-254, 
1979. 
Allonen, H., Ziegler, G., and Klotz, U. Midazolam Kinetics. 
C/in. Pharmacol. Ther., 30: 653-661, 1982. 
Alps, B. J., Harry, T.V. and Southgate, P. J. The 
Pharmacology of Lorazepam, a Broad-Spectrum 
Tranquillizer. Curr. Med. Res. Opin., 1: 239-261, 
1973. 
Ameer, B. and Greenblatt, D. J. Lorazepam: A Review of Its 
Clinical Pharmacological Properties and Therapeutic 
Uses. Drugs, 21: 161-200, 1981. 
Anton, A. H., Gravenstein, J. S. and Wheat, M. W. 
Extracorporeal Circulation and Endogenous Epinephrine 
and Norepinephrine in Plasma, Atrium and Urine in Man. 
Anesthesiology, 25: 262-269, 1964. 
Antonaccio, M. J. Pharmacology of Central Mechanisms 
Governing the Circulation. In M. J. Antonaccio (Ed.), 
Cardiovascular Pharmacology. New York: Raven Press, 
1977. 
Antonaccio, M. J. Cardiovascular Pharmacology of 
Anxiolytics. InS. Fielding and H. Lal (Eds.), 
Anxiolytics. Mount Kisco, New York: Futura Publishing 
Company, 1979. 
Antonaccio, M. J. and Halley, J. Inhibition of Centrally-
Evoked Pressor Responses by Diazepam: Evidence for an 
Exclusive Supramedullary Action. Neuropharmacology 
111: 649-657, 1975. 
174 
175 
Arkin, H. and Colton, R. R. Statistical Methods. New York: 
Barnes and Noble Books, 1970. 
Bailey, D. R., Miller, E. D., Kaplan, J. A. and Rogers, P.W. 
The Renin-Angiotensin-Aldosterone System During Cardiac 
Surgery with Morphine-Nitrous Oxide Anesthesia. 
Anesthesiology, '12: 538-544, 197 5. 
Balasaraswathi, K., Glisson, S. N., El-Etr, A. and Azad, C. 
Effect of Priming Volume on Serum Catecholamines During 
Cardiopulmonary Bypass. Can. Anaesth. Soc. J. , 27: 
135-139, 1980. 
Balasaraswathi, K., Glisson, S. N., El-Etr, A. and 
Mummaneni, N. Hemodynamic and Catecholamine Response 
to Isoflurane Anaesthesia in Patients Undergoing 
Coronary Artery Surgery. Can. Anaesth. Soc. J. , 29: 
533-538' 1982. 
Balasaraswathi, K., Glisson, S. N., El-Etr, A. A. and 
Pifarre, R. Serum Epeinephrine and Norepinephrine 
During Valve Replacement and Aorta-Coronary Bypass. 
Can. Anaesth. Soc. J., 25: 198-203, 1978. 
Barman, S. M. and Gebber, G. L. Pictrotoxin- and 
Bicuculline-Sensitive Inhibition of Cardiac Vagal 
Reflexes. J. Pharmacol. Exp. Ther., 209: 67-71, 
1979. 
Barta, E., Kvetnansky, R., Kuzela, L., Babusikova, F. and 
Mikulaj, L. Coronary A-V Difference of Plasma 
Dopamine-Beta-Hydroxylase Activity During Stress 
Situation of Cardiopulmonary Bypass in Patients. In E. 
Usdin, R. Kvetnansky and I. J. Kopin (Eds.), 
Catecholamines and Stress. Oxford: Pergamon Press, 
1976. 
Berne, R.M. and Levy, M.N. Cardiovascular Physiology. St. 
Louis: The C.V. Mosby Company, 1977. 
Braestrup, C., Albrechtsen, R., and Squires, R. F. High 
Densities of Benzodiazepine Receptors in Human Cortical 
Areas. Nature, 269: 702-704, 1977. 
Braestrup, C. and Squires, R. F. Specific Benzodiazepine 
Receptors in Rat Brain Characterized by High-Affinity 
3 H-Diazepam Binding. Proc Nat/. Acad. Sci. USA, 7'1: 
3805-3809, 1977. 
Braestrup, C. and Squires, R. F. Brain Specific 
Benzodiazepine Receptors. Br. J. Psychiatry, 133: 
249-260, 1978. 
Bromage, P.R., Shibata, H. R. and Willoughby, H. W. 
176 
Influence of Prolonged Epidural Blockade on Blood Sugar 
and Cortisol Responses to Operations upon the Upper 
Part of the Abdomen and the Thorax. Surg. Gynecol. 
Obstet., 132: 1051-1056, 1971. 
Buhler, F. R. Antihypertensive Beta-Blockade and the Renin-
Angiotensin System. Cardiology, 66 (Suppl. 1): 
12-27, 1980. 
Butler, M. J., Britton, B. J., Wood, W. G., Mainwaring-
Burton, R. and Irving, M. H. Plasma Catecholamine 
Concentrations During Operation. Br. J. Surg., 6Q: 
786-790, 1977. 
Cairns, J. A. Hemodynamic Monitoring in Acute Myocardial 
Infarction. Can. Med. Assoc. J., 121: 905-910, 
1979. 
Chai, C. Y. and Wang, S. C. Cardiovascular Actions of 
Diazepam in the Cat. J. Pharmacol. Exp. Ther., 15Q: 
271-280, 1966. 
Chan, C.-C. and Kalsner, S. Termination of Reponses to 
Sympathetic Nerve Stimulation and to Noradrenaline in a 
Perfused Arterial Preparation: The Role of Neuronal 
and Extraneuronal Uptake. J. Pharmacol. Exp. Ther., 
222: 731-740, 1982. 
Chen, R. Y. Z., Fan, F.-C., Schuessler, G. B. and Chien, S. 
Baroflex Control of Heart Rate in Humans During 
Nitroprusside-Induced Hypotension. Am. J. Physiol., 
2Q3 (Regulatory Integrative Comp. Physiol. 12): 
Rl8-R24, 1982. 
Chiba, S., Kozu, T.M., and Watanabe, H. Analysis of Cardiac 
Actions on Nitroprusside in Intact Dogs and in Isolated 
Atria. Jpn. Heart J., 23: 613-621, 1982. 
Cocchi, D., Casanueva, F., Locatelli, V. Apud, J., Martinez-
Campos, A., Civati, C., Racagni, G. and Muller, E. E. 
Gabaergic Mechanisms in the Control of PRL and GH 
Release. In E. Costa, G. Di Chiara and G. L. Gessa 
(Eds.), GABA and Benzodiazepine Receptors. New 
York: Raven Press, 1981. 
r 
Cohen, P.J. Signs and Stages of Anesthesia. In L.S. 
Goodman and A. Gilman (Eds.), The Pharmacological 
Basis of Therapeutics. New York: Macmillan 
Publishing Co., Inc., 1975. 
Conner, J. T., Katz, R. 1., Bellville, J. W., Graham, C., 
Pagano, R. and Dorey, F. Diazepam and Lorazepam for 
Intravenous Surgical Premedication. J. Clin. 
Pharmacal., 18: 285-292, 1978. 
Corrodi, H., Fuxe, K., Lidbrink, P. and Olson, L. Minor 
Tranquillizers, Stress and Central Catecholamine 
Neurons. Brain Res., 29: 1-16, 1971. 
177 
Cosgrove, D. 0. and Jenkins, J. S. The Effects of Epidural 
Anaesthesia on the Pituitary-Adrenal Response to 
Surgery. Clin. Sci. Mol. Med., '16: 403-407, 1974. 
Costa, E. and Guidotti. A. Recent Studies on the Mechanism 
Whereby Benzodiazepines Facilitate GABA-ergic 
Transmission. In P. Mandel and F. V. DeFeudis (Eds.), 
GABA -- Biochemistry and CNS Functions. New York: 
Plenum Press, 1979. 
Costa E., Guidotti, A. and Mao, C. C. Evidence for 
Involvement of GABA in the Action of Benzodiazepines: 
Studies on Rat Cerebellum. In E. Costa and P. 
Greengard (Eds.), Mechanism of Action of 
Benzodiazepines. New York: Raven Press, 1975. 
Cote, P., Gueret, P. and Bourassa, M.G. Systemic and 
Coronary Hemodynamic Effects of Diazepam in Patients 
with Normal and Diseased Coronary Arteries. 
Circulation, 50: 1210-1216, 1974. 
Cottrell, J. E., Illner, P., Kittay, M. J., Steele, J. M., 
Lowenstein, J. and Turndorf, H. Rebound Hypertension 
After Sodium Nitroprusside-Induced Hypotension. Clin. 
Pharmacal. Ther., 27: 32-36, 1980. 
Daniell, H. B. Cardiovascular Effects of Diazepam and 
Chlordiazepoxide. Eur. J. Pharmacal., 32: 58-65, 
1975. 
Davies, L. P. and Huston, V. Peripheral Benzodiazepine 
Binding Sites in Heart and their Interaction with 
Dipyridamole. Eur. J. Pharmacal., 33: 209-211, 1981. 
178 
Delaney, T. J. and Miller, E. D. Rebound Hypertension After 
Sodium Nitroprusside Prevented by Saralasin in Rats. 
Anesthesiology, 52: 154-156, 1980. 
DiMicco, J. A., Gale, K., Hamilton, B. and Gillis, R. A. 
GABA Receptor Control of Parasympathetic Outflow to 
Heart: Characterization and Brainstem localization. 
Science, 204: 1106-1109, 1979. 
DiMicco, J. A., Hamilton, B. L. and Gillis, R. A. Central 
Nervous System Sites Involved in the Cardiovascular 
Effects of Picrotoxin. J. Pharmacol. Exp. Ther., 
203: 64-71, 1977. 
Dundee, J. W. New I.V. Anaesthetics. Br. J. Anaesth., 51: 
641-648, 1979. 
Dundee, J. W., McGowan, W. A., Lilburn, J. K., McKay, A. C. 
and Hegarty J. E. Comparison of the Actions of 
Diazepam and Lorazepam. Br. J. Anaesth., 51: 
439-446' 1979. 
Dundee, J. W., Samuel, I. 0., Toner, W. and Howard, P. J. 
Midazolam: A Water-Soluble Benzodiazepine. 
Anaesthesia, 35: 454-458, 1980. 
Elliott, H. W. Metabolism of Lorazepam. Br. J. Anaesth., 
48 : 1 0 1 7 - 1 0 2 3 , 19 7 6 . 
Engquist, A. Brandt, M. R., Fernandes, A. and Kehlet, H. 
The Blocking Effect of Epidural Analgesia on the 
Adrenocortical and Hyperglycemic Responses to Surgery. 
Acta Anaesth. Scand., 21: 330-335, 1977. 
Enna, S. J. Regional Variation and Characteristics of GABA-
Receptors in the Mammalian CNS. In P. Mandel and F. V. 
DeFeudis (Eds.), GABA-Biochemistry and CNS 
Functions. New York: Plenum Press, 1979. 
Estafanous, F. G., Tarazi, R. C., Viljoen, J. F. and El 
Tawil, M. Y. Systemic Hypertension following 
Myocardial Revascularization. Am. Heart J. , 85: 
732-738, 1973. 
Favre, L., Vallotton, M. B. and Muller, A. F. Relationship 
between Plasma Concentrations of Angiotensin I, 
Angiotensin II and Plasma Renin Activity During Cardio-
pulmonary Bypass in Man. Eur. J. Clin. Invest., 4: 
135-140, 1974. 
179 
Forster, A. Utilisation of Midazolam as an Induction Agent 
in Anaesthesia. Arzneimittelforsch., 31 (12a): 2243, 
1981. 
Forster,A., Gardaz, J.P., Suter, P.M. and Gemperle, M. 
I.V. Midazolam as an Induction Agent for Anaesthesia: 
A Study in Volunteers. Br. J. Anaesth., 52: 907-911, 
1980. 
Fragen, R. J., Gahl, F. and Caldwell, N. A Water-Soluble 
Benzodiazepine, RO 21-3981, for Induction of 
Anesthesia. Anesthesiology, '19: 41-43, 1978. 
Fuxe, K. Agnati, F., Bolme, P., Hokfelt, T., Lidbrink, P., 
Ljungdahl, A., Perez de la Mora, M. and Ogren, S.-0. 
The Possible Involvement of GABA Mechanisms in the 
Action of Benzodiazepines on Central Catecholamine 
Neurons. In E. Costa and P. Greengard (Eds.), 
Mechanism of Action of Benzodiazepines. New York: 
Raven Press, 1975. 
Gallager, D. W., Mallorga, P., Thomas, J. W. and Tallman, J. 
F. GABA-Benzodiazepine Interactions: Physiological, 
Pharmacological and Developmental Aspects. Fed. 
Proc., 39: 3043-3049, 1980. 
Gale, G. and Galleon, S. Lorazepam as a Premedication. 
Can. Anaesth. Soc. J., 23: 22-29, 1976. 
Gamble, J. A. S., Kawar, P., Dundee, J. W., Moore, J. and 
Briggs, L. P. Evaluation of Midazolam as an 
Intravenous Induction Agent. Anaesthesia, 36: 
868-873' 1981. 
Gilbert, B. W. and Hew E. M. Physiologic Significance of 
Hemodynamic Measurements and their Derived Indices. 
Can. Med. Assoc. J., 121: 871-876, 1979. 
Gill, G. V., Prudhoe, K., Cook, D. B. and Latner, A. L. 
Effect of Surgical Trauma on Plasma Concentrations of 
Cyclic AMP and Cortisol. Br. J. Surg., 62: 441-443, 
1975. 
Glisson, S. N. Neurochemical Evicence for Cholinergic-
Adrenergic Coupling in Mammalian Central Nervous 
Systems. Ph.D. Dissertation, Loyola University, 
Chicago, Illinois, 1971. 
180 
Glisson, S. N., Karczmar, A. G. and Barnes, C. Cholinergic 
Effects on Adrenergic Neuro Transmitters in Rabbit 
Brain Parts. Neuropharmacology, 11: 465-577, 1972. 
Grandison, L. Anterior Pituitary GABA Receptors and their 
Regulation of Prolactin Secretion. In. E. Costa, G. Di 
Chiara and G. L. Gessa (Eds.), CABA and 
Benzodiazepine Receptors. New York: Raven Press, 
1981. 
Greenblatt, D. J. Clinical Pharmacokinetics of Oxazepam and 
Lorazepam. Clin. Pharmacokinet., 6: 89-105, 1981. 
Greenblatt, D. J., Comer, W. H., Elliott, H. W., Shader, R. 
I., Knowles, J. A. and Ruelius, H. W. Clinical 
Pharmacokinetics of Lorazepam. III. Intravenous 
Injection. Preliminary Results. J. Clin. Pharmacol., 
17: 490-494, 1977. 
Guyton, A. C. Textbook of Medical Physiology. 
Philadelphia: W. B. Saunders Company, 1976. 
Haber, E., Koerner, T., Page, L. B., Kimura, B., and 
Purnode, A. Application of Radioimmunoassay for 
Angiotensin I to the Physiologic Measurements of Plasma 
Renin Activity in Normal Human Subjects. J. Clin. 
Endocrinol. Metab., 29: 1349-1355, 1969. 
Haefely, W. Kulcsar, A., Mohler, H., Pieri, L., Pole, P. and 
Schaffner, R. Possible Involvement of GABA in the 
Central Actions of Benzodiazepines. In E. Costa and P. 
Greengard (Eds.), Mechanism of Action of 
Benzodiazepines. New York: Raven Press, 1975. 
Haggendal, J. An Improved Method for Fluorimetric 
Determination of Small Amounts of Adrenaline and 
Noradrenaline in Plasma and Tissues. Acta Physiol. 
Scand., 59: 242-254, 1963. 
Hall, R.M., and Boulton, T.B. Editorial. Anesthesia, 34: 
755-756, 1979. 
Halter, J. B., Pflug, A. E. and Porte, D., Jr. Mechanism of 
Plasma Catecholamine Increases During Surgical Stress 
inMan. J. C/in. Endocrinol. Metab., 45: 936-944, 
1977. 
181 
Hammond, W. G., Aronow, L. and Moore, F. D. Studies in 
Surgical Endocrinology. III. Plasma Concentrations of 
Epinephrine and Nor-epinephrine in Anesthesia, Trauma 
and Surgery, as Measured by a Modification of the 
Method of Weil-Malherbe and Bone. Ann. Surg., 1'1'1: 
715-732 1956. 
Hasbrouck, J. D. Morphine Anesthesia for Open-Heart 
Surgery. Ann. Thorac. Surg., 10: 364-369, 1970. 
Hegarty, J. E. and Dundee, J. W. Sequelae After the 
Intravenous Injection of Three Benzodiazepines --
Diazepam, Lorazepam, and F1unitrazepam. Br. Med. J., 
2: 1384-1385, 1977. 
Heizmann, P. and Ziegler, W. H. Excretion and Metabolism of 
14C-Midazolam in Humans following Oral Dosing. 
Arzneimittelforsch., 31 (12a): 2220-2223, 1981. 
Helwig, J. T. and Council, K. A. (Eds.). SAS User's 
Guide, 7979 Edition. Cary, North Carolina: SAS 
Institute Inc., 1979. 
Hickey, R.F., Eger, E.I. Circulatory Pharmacology of 
Inhaled Anesthetics. In R.D. Miller (Ed), Anesthesia. 
New York: Churchill Livingston, 1981. 
Hillestad, L., Hansen, T. Melsom, H. and Drivenes, A. 
Diazepam Metabolism in Normal Man. Clin. Pharmacal. 
Ther., 76: 479-484, 1974. 
Hine, I. P., Wood, W. G., Mainwaring-Burton, R. W., Butler, 
M. J., Irving, M. H. and Booker, B. The Adrenergic 
Response to Surgery Involving Cardiopulmonary Bypass, 
as Measured by Plasma and Urinary Catecholamine 
Concentratins. Br. J. Anaesth., 48: 355-363, 1976. 
Hoar, P. F., Hickey, R. F. and Ullyot, D. J. Systemic 
Hypertension following Myocardial Revascularization. 
J. Thorac. Cardiovasc. Surg., 71: 859-864, 1976. 
Hoar, P. F., Nelson, N. T., Mangano, D. T., Bainton, C. R. 
and Hickey, R. F. Adrenergic Responses to Morphine-
Diazepam Anesthesia for Myocardial Revascularization. 
Anesth. Ana/g., 60: 406-411, 1981. 
Hoar, P. F., Nelson, N. T., Mangano, D. T., Hickey, R. F. 
and Bainton, C. R. Adrenergic Response to Morphine and 
Valium Anesthesia. Anesthesiology, 53: S105, 1980a. 
182 
Hoar, P.F., Stone, J.G., Faltas, A.N., Bendixen, H.H., Head, 
R.J. and Berkowitz, B.A. Hemodynamic and Adrenergic 
Responses to Anesthesia and Operation for Myocardial 
Revascularization. J. Thorac. Cardiovasc. Surg., 80: 
242-248, 1980b. 
Ikram, H., Rubin, A. P. and Jewkes, R. F. Effect of 
Diazepam on Myocardial Blood Flow of Patients with and 
without Coronary Artery Disease. Br. Heart J., 35: 
626-630, 1973. 
Iverson, L.L. and Salt, P.J. Inhibition of Catecholamine 
Uptake-2 by Steriods in the Isolated Rat Heart. Br. 
J. Pharmacal., ~0: 528-530, 1970. 
Innes, I.R. and Nickerson, M. Norepinephrine, Epinephrine, 
and the Sympathomimetic Amines. In L.S. Goodman and A. 
Gilman (Eds.), The Pharmacological Basis of 
Therapeutics. New York: Macmillan Publishing Co., 
Inc., 1975. 
James, M. and Fisher, A. Nitrazepam as a Premedicant in 
Minor Surgery. Anaesthesia, 25: 364-367, 1970. 
Jones, D. J., Stehling, L. C. and Zauder, H. L. 
Cardiovascular Responses to Diazepam and Midazolam 
Maleate in the Dog. Anesthesiology, 51: 430-434, 
1979. 
Kaneko, Y., Ikeda, T., Takeda, T. and Ueda, H. Renin 
Release During Acute Reduction of Arterial Pressure in 
Normotensive Subjects and Patients with Renovascular 
Hypertension. J. Clin. Invest., ~6: 705-716, 1967. 
Kaplan, J. A. Hemodynamic Monitoring. In J. A. Kaplan 
(Ed.) , Cardiac Anesthesia. New York: Grune and 
Stratton, 1979. 
Kaplan, J.A., Cardiovascular Physiology. In R.D. Miller 
(Ed), Anesthesia. New York: Churchill Livingston, 
1981. 
Kaplan, S. A., Jack, M. L., Alexander, K. and Weinfeld, R. 
E. Pharmacokinetic Profile of Diazepam in Man 
following Single Intravenous and Oral and Chronic Oral 
Administrations. J. Pharm. Sci., 62: 1789-1796, 
1973. 
Kehlet, H., Binder, C. and Engbaek, C. Cortisol Binding 
Capacity in Plasma During Anaesthesia and Surgery. 
Acta Endocrinol., 75: 119-125, 1974. 
Khambatta, H. J., Stone, J. G. and Khan, E. Hypertension 
During Anesthesia on Discontinuation of Sodium 
Nitroprusside-Induced Hypotension. Anesthesiology, 
51: 127-130, 1979. 
183 
Kim, Y. D., Jones, M., Hanowell, S. T., Koch, J.P., Lees, 
D. E., Weise, V. and Kopin, I. J. Changes in 
Peripheral Vascular and Cardiac Sympathetic Activity 
Before and After Coronary Artery Bypass Surgery: 
Interrelationships with Hemodynamic Alterations. Am. 
Heart J., 102: 972-979, 1981. 
Kirk, R. E. Experimental Design: Procedures for the 
Behavioral Sciences. Belmont, California: Brooks/Cole 
Publishing Company, 1968. 
Klepner, C. A., Lippa, A. S., Benson, D. I., Sana, M. C. and 
Beer, B. Resolution of Two Biochemically and 
Pharmacologically Distinct Benzodiazepine Receptors. 
Pharmacol. Biochem, Behav., 11: 457-462, 1979. 
Klotz, U., Antonin, K. H. and Bieck, P.R. Pharmacokinetics 
and Plasma Binding of Diazepam in Man, Dog, Rabbit, 
Guinea Pig and Rat. J. Pharmaco/. Exp. Ther., 199: 
67-73, 1976. 
Knapp, R. B. and Fierro, L. Evaluation of the 
Cardiopulmonary Safety and Effects of Lorazepam as a 
Premedicant. Anesth. Analg., 53: 122-12'1, 197'1. 
Kothary, S. P., Zsigmond E. K. and Matsuki, A. Antagonism 
of the Ketamine Induced Rise in Plasma Free 
Norepinephrine, Blood Pressure and Pulse Rate by 
Intravenous Diazepam. Clin. Pharmaco/. Ther., 17: 
238, 1975. 
Kumar, S.M., Kothary, S. P. and Zsigmond, E. K. Plasma 
Free Norepinephrine and Epinephrine Concentrations 
following Diazepam-Ketamine Anesthesia in Patients 
Undergoing Cardiac Surgery. Acta Anaesthesia/. 
Scand., 22: 593-600, 1978. 
Kumar, S.M., Kothary,, S. P. and Zsigmond, E. K. Lack of 
Cardiovascular Stimulation During Endotracheal 
Intubation in Cardiac Surgical Patients Anesthetized 
with Diazepam-Ketamine-Pancuronium. Clin. Ther., 3: 
43-48, 1980. 
Lappas, D. G., Fahmy, N. R., Moss, J. and Slater, E. E. 
184 
Effects of Fentanyl-Diazepam Anesthesia on 
Hemodynamics, Plasma Catecholamines and Renin Activity 
in Critically-Ill Patients. Anesthesiology, 55: 
A250, 1981. 
Le Fur, G., Guilloux, F., Mitrani, N., Mizoule, J. and Uzan, 
A. Relationships between Plasma Corticosteroids and 
Benzodiazepines in Stress. J. Pharmacol. Exp. Ther., 
211: 305-308, 1979. 
Lewis, R. N. Plasma Hydrocortisone Concentrations in 
Relation to Anaesthesia and Surgery. Br. J. Anaesth., 
35: 84-90, 1963. 
Lidbrink, P. and Farnebo, L.-0. Uptake and Release of 
Noradrenaline in Rat Cerebral Cortex in Vitro: No 
effect of Benzodiazepines and Barbiturates. 
Neuropharmacology, 12: 1087-1095, 1973. 
Lippa, A. S., Critchett, D., Sano, M. C., Klepner, C. A., 
Greenblatt, E. N., Coupet, J. and Beer, B. 
Benzodiazepine Receptors: Cellular and Behavioral 
Characteristics. Pharmacol. Biochem. Beh., 10: 
831-843, 1979. 
Madsen, S. N., Brandt, M. R., Engquist, A., Badawi, I. and 
Kehlet, H. Inhibition of Plasma Cyclic AMP, Glucose 
and Cortisol Response to Surgery by Epidural Analgesia. 
Br. J. Surg., 611: 669-671, 1977. 
Madsen, S. N., Engquist, A., Badawi, I. and Kehlet, H. 
Cyclic AMP, Glucose and Cortisol in Plasma During 
Surgery. Horm. Metab. Res., 8: 483-485, 1976. 
Madsen, S. N., Fog-Moiler, F., Christiansen, C., Vester-
Andersen, T. and Engquist, A. Cyclic AMP, Adrenaline 
and Noradrenaline in Plasma During Surgery. Br. J. 
Surg., 65: 191-193, 1978. 
Mandelli, M., Tognoni, G. and Garattini, S. Clinical 
Pharmacokinetics of Diazepam. Clin. Pharmacokinet., 
3: 72-91, 1978. 
185 
Makara, G. B. and Stark E. Effect of Gamma-Aminobutyric 
Acid (GABA) and GABA Antagonist Drugs on ACTH Release. 
Neuroendocrinology, 16: 178-190, 1974. 
Markiewicz, W., Hunt, S., Harrison, D. C. and Alderman, E. 
L. Circulatory Effects of Diazepam in Heart Disease. 
J. Clin. Pharmacol., 16: 637-61111, 1976. 
Martin, I. L. and Candy, J. 
Benzodiazepine Binding 
by a Number of Anions. 
175-179, 1980. 
M. Facilitation of Specific 
in Rat Brain Membrane Fragments 
Neuropharmacology, 19: 
McCammon, R. L., Hilgenberg, J. C. and Stoelting, R. K. 
Hemodynamic Effects of Diazepam and Diazepam-Nitrous 
Oxide in Patients with Coronary Artery Disease. 
Anesth. Analg., 59: 438-441, 1980. 
McCann, S.M., Vijayan, E. and Negro-Vilar, A. Role of 
Gamma Aminobutyric Acid in Control of Anterior 
Pituitary Hormone Release. In E.Costa, G. Di Chiara 
and G. L. Gessa (Eds.), CABA and Benzodiazepine 
Receptors. New York: Raven Press, 1981. 
McClish, A. Diazepam as an Intravenous Induction Agent for 
General Anaesthesia. Can. Anaes. Soc. J., 13: 
562-575, 1966. 
Melsom, M., Andreassen, P., Melsom, H., Hansen, T., 
Grendahl, H. and Hillestad, L, K. Diazepam in Acute 
Myocardial Infarction. Clinical Effects and Effects on 
Catecholamines, Free Fatty Acids and Cortisol. Br. 
Heart J., 38: 804-810, 1976. 
Melvin, M.A., Johnson, B. H., Quasha, A. L. and Eger II, E. 
I. Induction of Anesthesia with Midazolam Decreases 
Halothane MAC in Man. Anesthesiology, 53: S10, 1980. 
Miller, E. D., Ackerly, J. A., Vaughan, E. D., Peach, M. J. 
and Epstein, R. M. The Renin-Angiotensin System During 
Controlled Hypotension with Sodium Nitroprusside. 
Anesthesiology, 117: 257-252, 1977. 
Mohler, H. and Okada, T. Benzodiazepine Receptors: 
Demonstration in the Central Nervous System. Science, 
198: 849-851, 1977. 
186 
Morel, D., Forster, A., Gardaz, J.-P., Suter, P.M. and 
Gemperle, M. Comparative Hemodynamic and Respiratory 
Effects of Midazolam and Flunitrazepam as Induction 
Agents in Cardiac Surgery. Arzneimittelforsch., 31 
(12a): 2264-2267, 1981. 
Newsome, H. H. and Rose, J. C. The Response of Human 
Adrenocorticotrophic Hormone and Growth Hormone to 
Surgical Stress. J. Clin. Endocrinol. Metab., 33: 
481-487, 1971. 
Nickerson, M. and Ruedy, J. Antihypertensive Agents and the 
Drug Therapy of Hypertension. In L. S. Goodman and A. 
Gilman (Eds.), The Pharmacological Basis of 
Therapeutics. New York: Macmillan Publishing Co., 
Inc., 1975. 
Nicol, C.J.M. and Rae, R.M. Inhibition of Accumulation of 
Adrenaline and Noradrenaline in Arterial Smooth Muscle 
by Steriods. Br. J. Pharmacal., '1'1: 361P-362P, 1972. 
Nishi, S., Minota, S. and Karczmar, A. G. Primary Afferent 
Neurons: The Ionic Mechanim of GABA-Mediated 
Depolarization. Neuropharmacology, 13: 215-219, 
1974. 
Oka, Y., Wakayama, S., Oyama, T., Orkin, L. R., Becker, R. 
M., Blaufox, M.D. and Frater, R. W. Cortisol and 
Antidiuretic Hormone Responses to Stress in Cardiac 
Surgical Patients. Can. Anaesth. Soc. J. , 28: 
334-339, 1981. 
Oyama, T., Latto, P. and Holaday, D. A. Effect of 
Isoflurane Anaesthesia and Surgery on Carbohydrate 
Metabolism and Plasma Cortisol Levels in Man. Can. 
Anaesth. Soc. J., 22: 696-702, 1975. 
Oyama, T., Taniguchi, K., Ishihara, H., Matsuki, A., Maeda, 
A., Murakawa, T. and Kudo, T. Effects of Enflurane 
Anaesthesia and Surgery on Endocrine Function in Man. 
Br. J. Anaesth., 51: 141-147, 1979. 
Oyama, T., Taniguchi, K., Jin, T., Saton E. T. and Kudo, T. 
Effects of Anaesthesia and Surgery on Plasma 
Aldosterone Concentration and Renin Activity in Man. 
Br. J. Anaesth., 51: 747-751, 1979. 
Palmer, R.F., and Lasseter, K.C. Sodium Nitroprusside. N. 
Engl. J. Med. 292: 294-297, 1975. 
Paul, S. M., Marangos, P. J. and Skolnick, P. The 
Benzodiazepine-GABA-Chloride Ionophore Receptor 
Complex: Common Site of Minor Tranquilizer Action. 
Bioi. Psychiatry, 16: 213-229, 1981. 
Perry, L. B., Van Dyke, R. A. and Theye, R. A. 
187 
Sympathoadrenal and Hemodynamic Effects of Isoflurane, 
Halothane and Cyclopropane in Dogs. Anesthesiology, 
40: 465-470, 1974. 
Pflug, A. E. and Halter, J. B. Effect of Spinal Anesthesia 
on Adrenergic Tone and the Neuroendocrine Responses to 
Surgical Stress in Humans. Anesthesiology, 55: 
120-126, 1981. 
Philbin, D. M., Coggins, C. H., Emerson, C. W., Levine, F. 
H. and Buckley, M. Plasma Vasopressin Levels and 
Urinary Sodium Excretion During Cardiopulmonary Bypass. 
J. Thor. Cardiovasc. Surg., 77: 582-585, 1979. 
Pieri, L., Schaffner, R., Scherschlicht, R., Pole, P., 
Sepinwall, J., Davidson, A., Mohler, H., Cumin, R., Da 
Prada, M., Burkard, W. P., Keller, H. H., Muller, R. K. 
M., Gerold, M., Pieri, M., Cook, L. and Haefely, W. 
Pharmacology of Midazolam. Arzneimittelforsch., 31 
(12a): 2180-2201, 1981. 
Plumpton, F. S. and Besser, G. M. The Adrenocortical 
Response to Surgery and Insulin-Induced Hypoglycaemia 
in Corticosteriod-Treated and Normal Subjects. Br. J. 
Surg., 56: 216-219, 1969. 
Racagni, G., Apud, J. A., Civati, C., Cocchi, D., Casanueva, 
F., Locatelli, V., Nistico, G. and Muller, E. E. 
Neurochemical Aspects of GABA and Glutamate in the 
Hypothalamo-Pituitary System. In E. Costa, G. Di 
Chiara and G. L. Gessa (Eds.), GABA and 
Benzodiazepine Receptors. New York: Raven Press, 
1981. 
Rawlinson, W. A., Loach, A. B., and Benedict, C. R. Changes 
in Plasma Concentration of Adrenaline and Noradrenaline 
in Anaesthetized Patients During Sodium Nitroprusside-
Induced Hypotension. Br. J. Anaesth., 50: 937-943, 
1978. 
Reier, C. E., George, J. M. and Kilman, J. W. 
Growth Hormone Response to Surgical Stress 
Morphine Anesthesia. Anesth. Analg., 52: 
1973. 
Cortisol and 
During 
1003-1010, 
188 
Replogle, R., Levy, M., Dewall, R.A., and Lillehie, R.C. 
Catecholamine and Serotonin Response to Cardiopulmonary 
Bypass. J. Thorac. Cardiocasc. Surg., 'Ill: 638-648, 
1962. 
Reves, J. G., Corssen, G. and Holcomb, C. Comparison of Two 
Benzodiazepines for Induction: Midazolam and Diazepam. 
Can. Anaesth. Soc. J., 25: 211-214, 1978. 
Reves, J. G., Karp, R. B., Buttner, E. E., Tosone, S., 
Smith, L. R., Samuelson, P. N., Kreusch, G. R. and 
Oparil, S. Neuronal and Adrenomedullary Catecholamine 
Release in Response to Cardiopulmonary Bypass in Man. 
Circulation, 66: 49-55, 1982. 
Reves, J. G., Mardis, M. and Strong, S. Cardiopulmonary 
Effects of Midazolam. Ala. J. Med. Sci., 15: 
347-351, 1978. 
Reves, J. G., Samuelson, P. N. and Lewis, S. Midazolam 
Maleate Induction in Patients with Ischaemic Heart 
Disease: Haemodynamic Observations. Can. Anaesth. 
Soc. J., 26: 402-409, 1979. 
Reves, J. G., Vinik, R., Hirschfield, A.M., Holcomb, C. and 
Strong, S. Midazolam Compared with Thiopentone as a 
Hypnotic Component in Balanced Anaesthesia: A 
Randomized, Double-Blind Study. Can. Anaesth. Soc. 
J., 26: 42-49, 1979. 
Roberts, A. J., Niarchos, A. P., Subramanian, V. A., Abel, 
R. M., Herman, S. D., Sealey, J. E., Case, D. B., 
White, R. P., Johnson, G. A., Laragh, J. H. and Gay, W. 
A. Systemic Hypertension Associated with Coronary 
Artery Bypass Surgery. J. Thorac. Cardiovasc. Surg., 
74: 846-859, 1977. 
Roche Laboratories, Nipride package insert, August, 1982. 
Roizen, M. F., Hamilton, W. K. and Sohn, Y. J. Treatment of 
Stress-Induced Increases in Pulmonary Capillary Wedge 
Pressure Using Volatile Anesthetics. Anesthesiology, 
55: 446-450, 1981. 
Roizen, M. F., Moss, J., Henry, D.P. and Kopin, I. J. 
Effects of Halothane on Plasma Catecholamines. 
Anesthesiology, '11: 432-439, 1974. 
Rowe, G.G., and Henderson, R.H. Systemic and Coronary 
Hemodynamic Effects of Sodium Nitroprusside. Am. 
Heart J., 87: 83-87, 1974. 
189 
Samuelson, P. N., Lell, W. A., Kouchoukos, N. T., Strong, S. 
D. and Dole, K. M. Hemodynamics During Diazepam 
Induction of Anesthesia for Coronary Artery Bypass 
Grafting. South. Med. J., 73: 332-334, 1980. 
Samuelson, P. N., Reves, J. G., Kouchoukos, N. T., Smith, L. 
R. and Dole, K. M. Hemodynamic Responses to Anesthetic 
Induction with Midazolam or Diazepam in Patients with 
Ischemic Heart Disease. Anesth. Analg., 60: 802-809, 
1981. 
Schwander, D. and Sansano, C. Cardiovascular Changes During 
Intubation with Midazolam as Anaesthesia Inducing 
Agent. Arzneimittelforsch., 31 (12a): 2255-2260, 
1981. 
Sigg, E. B., Keim, K. L. and Kepner, K. Selective Effect of 
Diazepam on Certain Central Sympathetic Components. 
Neuropharmacology, 10: 621-629, 1971. 
Skultety, F. and Nishioka, H. The Results of Intracranial 
Surgery in the Treatment of Aneurysms. J. Neurosurg., 
25: 683-704, 1966. 
Smith, N. T., Eadie, M. J. and Brophy, T. 0. The 
Pharmacokinetics of Midazolam in Man. Eur. J. Clin. 
Phamacol., 19: 271-278, 1981. 
Smith, N.T., Calverley, R.K., Prys-Roberts, C., Eger, 
E.J.,II and Jones, C.W. Impact of Nitrous Oxide on the 
Circulation during Enflurane Anesthesia in Man. 
Anesthesiology, 118: 345-349, 1978. 
Speth, R. C., Johnson, R. W., Regan, J., Reisine, T., 
Kobayash, B., Resolin, N., Roeske, W. R. and Yamamura, 
H. I. The Benzodiazepine Receptor of Mammalian Brain. 
Fed. Proc., 39: 3032-3038, 1980. 
Squires, F. R., Benson, D. I., Braestrup, C., Coupet, J., 
Klepner, C. A., Myers, V., Beer,B. Some Properties of 
Brain Specific Benzodiazepine Receptors: New Evidence. 
Pharmacol. Biochem. Beh., 10: 825-830, 1979. 
Squires, R. F. and Braestrup, C. 
in Rat Brain. Nature, 266: 
Benzodiazepine Receptors 
732-734, 1977. 
190 
Stanek, B., Zimpfer, M., Fitzal, S. and Raberger, G. Plasma 
Catecholamines, Plasma Renin Activity and Haemodynamics 
During Sodium Nitroprusside-Induced Hypotension and 
Additional Beta-Blockade with Bunitrolol. Eur. J. 
Clin. Pharmacol., 19: 317-322, 1981. 
Swales, J. D. Renin-Angiotensin System in Hypertension. 
Pharmac. Ther., 7: 173-201, 1979. 
Sweet, C. S. Pharmacological Aspects of the Renin-
Angiotensin System. In M. J. Antonaccio (Ed.), 
Cardiovascular Pharmacology. New York: Raven Press, 
1977. 
Sweet, C. S., Wenger, H. C. and Gross, D. M. Central 
Antihypertensive Properties of Muscimol and Related 
Gamma-aminobutyric Acid Agonists and the Interaction of 
Muscimol with Baroreceptor Reflexes. Can. J. Physiol. 
Pharmacol. , 57: 600-605, 1979. 
Tallman, J. F., Thomas, J. W. and Gallager, D. W. GABAergic 
Modulation of Benzodiazepine Binding Site Sensitivity. 
Nature, 2Jq: 383-385, 1978. 
Tan, C., Glisson, S. N., E1-Etr, A. A. and Younes, S. H. 
Adrenal Responses to Anesthetics During Cardiopulmonary 
Bypass. Cardiovasc. Med. 3: 521-528, 1978. 
Tappaz, M. L., Aguera, M., Belin, M. F., Oertel, W. H., 
Schmechel, D. E., Kopin, I. J. and Pujol, J. F. GABA 
Markers in the Hypothalamic Median Eminence. In E. 
Costa, G. Di Chiara and G. L. Gessa (Eds.), CABA and 
Benzodiazepine Receptors. New York: Raven Press, 
1981. 
Taylor, K. M., Jones, J. V., Walker, M. S., Rao, S. and 
Bain, W. The Cortisol Response During Heart-Lung 
Bypass. Circulation, 5q: 20-25, 1976. 
Taylor, K. M. and Laverty, R. The Interaction of 
Chlordiazepoxide, Diazepam, and Nitrazepam with 
Catecholamines and Histamine in Regions of the Rat 
Brain. In S. Garattini, E. Mussini and L. 0. Randall 
(Eds.), The Benzodiazepines. New York: Raven Press, 
1973. 
Taylor, K. M., Morton, I. J., Brown, J. J., Bain, W. H. and 
Caves, P. K. Hypertension and the Renin-Angiotensin 
System following Open-Heart Surgery. J. Thor. 
Cardiovasc. Surg., 7q: 840-845, 1977. 
191 
Turndorf, H. Discussion of C. E. Reier, J. M. George, J. W. 
Kilman, Cortisol and Growth Hormone Response to 
Surgical Stress During Morphine Anesthesia. Anesth. 
Ana/g., 52: 1009-1010, 1973 
Turton, M. B., Deegan, T. and Coulshed, N. Plasma 
Catecholamine Levels and Cardiac Rhythm Before and 
After Cardiac Catheterization. Br. Heart J., 39: 
1307-1311, 1977. 
Van Ackern, K., Franke, N., Peter, K. and Schmucker, P. 
Enflurane in Patients with Coronary Artery Disease. 
Acta Anaesthesiol Scand. (Suppl.), 71: 71-76, 1979. 
Vendsalu, A. Studies on Adrenalin and Noradrenalin in Human 
Plasma. Acta Physiol. Scand. (Suppl. 173), q.g: 
1-123, 1960 
Viljoen, J. F., Estafanous, F. G. and Tarazi, R. C. Acute 
Hypertension Immediately After Coronary Artery Surgery. 
J. Thorac. Cardiovasc. Surg., 71: 548-550, 1976. 
Vlachakis, N.D., Pratilas, V. and Pratila, M. Raised 
Plasma Catecholamines. N. Y. State J. Med., 81: 
27-35' 1981. 
Vree, T. B., Baars, A.M., Booij, L. H. D. and Driessen, J. 
J. Simultaneous Determination and Pharmacokinetics of 
Midazolam and its Hydroxymetabolites in Plasma and 
Urine of Man and Dog by Means of High-Performance 
Liquid Chromatography. Arzneimittelforsch., 31 (12a): 
2215-2219, 1981. 
Wallenstein, S. Zucker, C. L. and Fleiss, J. L. Some 
Statistical Methods Useful in Circulation Research. 
Circ. Res., q.J: 1-9, 1980. 
Wesseling, H. and Edens, E. T. Effect of Premedication on 
Stress and Plasma Cortisol in Patients Bronchoscoped 
under Local Anaesthesia. Eur. J. Clin. Pharmacol., 8: 
323-326, 1975. 
White, R. D. Monitoring Arrhythmias and Signs of 
Intraoperative Ischemia by Electrocardiogram. Cleve. 
C/in. Q., q.8: 32-36, 1981. 
Wilson, J. Lorazepam as a Premedicant for General 
Anaesthesia. Curr. Med. Res. Opin., 1: 308-316, 
1973. 
192 
Winer, B. J. Statistical Principles in Experimental Design. 
New York: McGraw-Hill Book Company, 1962. 
Yoga, H., Sasaki, T., Yamaoka, T., Naruse, T. and Itasaka, 
Y. Response of Plasma Renin Activity During Surgical 
Stress. Jpn. J. Surg., 3: 203-211, 1973. 
Yokota, H., Kawashima, Y., Hashimoto, S., Manabe, H., 
Onishi, T., Aono, T. and Matsumoto, K. Plasma 
Cortisol, Luteinizing Hormone (LH), and Prolactin 
Secretory Responses to Cardiopulmonary Bypass. J. 
Surg. Res., 23: 196-200, 1977. 
Yun, J. C., Donahue, J. J., Bartter, F. C. and Kelly, G. D. 
Effect of Pentobarbital Anesthesia and Laparotomy on 
Plasma Renin Activity in the Dog. Can. J. Physiol. 
Pharmacal., 57: 412-416, 1979. 
Zivin, J. A. and Bartko, J. J. 
Scientists. Life Sci., 18: 
Statistics for Disinterested 
15-26, 1976. 
Zsigmond, E. K., Kothary, S. P., Kumar, S.M. and Kelsch, R. 
C. Counteraction of Circulatory Side Effects of 
Ketamine by Pretreatment with Diazepam. Cli n. T her. , 
3: 28-32, 1980. 
Zsigmond, E. K., Kothary, S. P., Matsuki, A. and Kelsch, R. 
C. Diazepam for Prevention of the Rise in Plasma 
Catecholamines Caused by Ketamine. Clin. Pharmacal. 
Ther., 15: 223-224, 1974. 
APPENDIX A 
TABLE 8 
ANALYSIS OF VARIANCE FROM EXPERIMENT I 
F-Ratio 
Drug Time Drug*Time 
Blood Pressure 0.5 328.6* 1.0 
Heart Rate 0.3 2.6* 0.6 
Cardiac Index 2.2 12.7* 1.3 
Right Atrial Pressure 0.3 3.8* 1.0 
Systemic Vascular Resistance Index 1.8 27.8* 0.8 
Wedge Pressure 1.2 2.7* 1.0 
Stroke Work index 2.2 80.5* o·. g 
Epinephrine 7.2* 4.3* 1.7 
Norepinephrine 6.0* 0.5 2.2* 
1-' 
Cortisol 2.2 10.4* 1.5 \0 
-'=" 
Renin Activity 0.6 24.3* 1.1 .. 
*p less than .OS 
TABLE 9 
.. _ 
ANALYSIS OF VARIANCE FROM EXPERIMENT II 
F .. Ratio 
Drug Time Drug*Time 
•, 
Blood Pressure 1.6 119.0* 0.3 
Heart Rate 0.8 3.7* 0.4 
Cardiac Index 7.1* 12.'9* 0.6 
Right Atrial Pressure 1.6 6. O*· 1.7 
Systemic Vascular Resistance Index 7.2* 15.7* 0.8 
Wedge Pressure 2.9 7.3* 3.5* 
Stroke Work Index 0.3 65.9* 0.9 
Epinephrine 7.0* 4.8* 1.5 
Norepinephrine 4.8* 2.1 0.8 
..... 
Cortisol 0.8 15.7* 2.9* \0 VI 
*p less than .OS 
TABLE .10 
ANALYSIS OF VARIANCE FROM EXPERIMENT III 
F-Ratio 
Drug Time Drug*Time 
Blood Pres'sure 0.1 14.6* 1.0 
Heart Rate 3.2 6.3* 0.2 
Cardiac Index 1.2 6.4* 0.2 
Right Atrial Pressure 0.1 1.3 2.0 
Systemic Vascular Resistance Index 1.5 1.4 0.5 
Wedge Pressure o.o 3.1* 0. 5 
Stroke Work Index -2.3 11.3* 0.4 
Epinephrine 9.0* 0.8 1.0 
Norepinephrine 3.2 0.5 1.0 
Cortisol 0.3 3.7* 1.0 
Renin Activity 2.8 8.3"' 3.2* 
*p less than .OS 
TABLE 11 
ANALYSIS OF VARIANCE 
FROM POSTINCISION BLOOD PRESSURE AND HEART RATE 
Blood Pressure 
Heart Rate 
*p less than .OS 
Drug 
0.7 
1.4 
F-Ratio 
Time 
2.7* 
3. 7.* 
Drug*Time 
5.0* 
1.7 
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TABLE 12 
TYPICAL PLASMA EPINEPHRINE STANDARD CURVE DATA 
Sample Epinephrine NET FLUOROMETRIC UNITS 
Concentration 
(ng/ml} 400/505 nM 450/505 nM 
1 9 3 
2.5 24 8 
5 45 16 
10 95 36 
15 147 57 
20 195 77 
25 249 95 
50 507 195 
200 
TABLE 13 
TYPICAL PLASMA NOREPINEPHRINE STANDARD CURVE DATA 
Sample Norepinephrine NET FLUOROMETRIC UNITS 
Concentration 
(ng/ml) 400/505 nM 450/505 nM 
1 4 1 
2.5 9 1 
5 20 2 
10 48 5 
15 75 7 
20 100 10 
25 127 12 
50 263 13 
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TABLE 14 
TYPICAL PLASMA CORTISOL STANDARD CURVE DATA 
Sample Cortisol 
Concentration 
(mcg/dl) %B/Bo1 
1.0 80.2 
1.0 80.3 
4.3 60.0 
4.3 59.3 
10.6 42.2 
10.6 41.9 
28.6 25.2 
28.6 25.9 
60.9 17.4 
60.9 17.2 
lB = Sample Counts 
Bo = Average Zero Standard Counts 
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TA.BLE 1.5 
TYPICAL PLASMA RENIN ACTIVITY STARDARD CURVE DATA 
Sample Angiotensin I 
(ng/tube) %B/Bo1 
.020 74.7 
.020 71.6 
.040 56.0 
.040 60.4 
.080 39.6 
.080 38.1 
.l25 30.0 
.l25 28.6 
.250 16.1 
.250 15.7 
.500 8.1 
.500 9.1 
lB = Sample Counts 
Bo = Average Zero Standard Counts 
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